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Abstract 
The non-classical HLA class Ib genes, HLA-E, -F, and -G, are the only HLA genes found to be 
expressed in trophoblast cells in the placenta along with low expression of HLA-C. HLA-G, which is 
the best studied of the non-classical HLA class Ib molecules, has been found to be implicated in 
pregnancy complications due to its immunomodulatory function at the feto-maternal interface. As 
the structure and expression of HLA-F resemble that of the other class Ib molecules, especially 
HLA-G, it is hypothesized that it might also play an important immunological role during 
pregnancy. The aim of this case-control study is to examine the possible immunological 
association between polymorphisms in the HLA-F gene and Recurrent Spontaneous Abortions. In 
order to elucidate this hypothesis, polymerase chain reaction (PCR) amplifications of the 5’ URR 
and 3’ UTR of HLA-F from DNA samples derived from RSA patients and a control group are 
conducted and compared.   
Abstrakt  
De nonklassiske HLA klasse Ib gener, HLA-E, -F, and -G er de eneste HLA gener, der udtrykkes i 
trophoblastceller i placenta sammen med et lavt udtryk af HLA-C. HLA-G, som er det bedst 
undersøgte nonklassiske HLA-Ib molekyle, har vist sig at være involveret i 
graviditetskomplikationer grundet dets immunmodulerende rolle i grænsefladen mellem moder 
og foster. Da HLA-F, både med hensyn til struktur og expression minder om HLA-G, som er et 
andet nonklassisk HLA Ib molekyle, kunne det antages, at HLA-F også kunne have en vigtig 
immunologisk rolle under graviditeten. Formålet med dette case-control studie er at klarlægge en 
mulig immunologisk forbindelse mellem polymorfier i HLA-F og udviklingen af gentagne spontane 
aborter. For at belyse denne problematik udføres en polymerase chain reaction (PCR) 
amplifikation, hvor 5’-URR- og 3’-UTR-områderne af HLA-F-genet amplificeres hos patienter med 
gentagne spontane aborter og en kontrol gruppe.  
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Preface 
This bachelor project is devised at Roskilde University in cooperation with the Department of 
Clinical Biochemistry at Roskilde Hospital and aims to elucidate the possible role of HLA-F 
polymorphisms in the development of Recurrent Spontaneous Abortions (RSA), through literature 
studies and experimental procedures.  
The non-classical HLA class Ib molecules are all expressed in the placenta, on the cell surface of 
trophoblast cells, as opposed to the classical HLA molecules, expect HLA-C which is also found to 
be expressed on trophoblast cells. As the reasons for the development of RSA in some cases are 
yet to be found, the focus in Part I will be the implication of HLA-E and -F  on RSA, whereas the 
focus in Part II will be to elucidate a possible association between polymorphisms in HLA-F and 
RSA. The hypothesis of such an association is based on the fact that the other HLA molecules 
which are found to be expressed on trophoblast cells have been reported to be implicated in the 
development of tolerance against the semi-allogeneic fetus. Polymorphisms in these genes have 
been found to be associated with women experiencing pregnancy complications, however this is a 
controversial issue.  
The project is thought as a contribution to research within RSA and is directed to researchers 
within the field of immunology and RSA.  
A list of abbreviations used throughout the text is to be found in the beginning of the project. 
Furthermore, the consensus sequences of HLA class I genes are to be found in Appendix I, whereas 
the data obtained in this study is given in Appendix II. Gene designations are written in italics. 
We would like to thank our associate professor, Louise Torp Dalgaard, and our supervisor, Chief 
Physician, MD, PhD, DMSc Thomas Vauvert Hviid for their guidance throughout the project.  
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EBV Epstein-Barr virus  
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IL-2 Interleukin-2 
ILT Immunoglobulin-like transcript 
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RA Rheumatoid Arthritis 
RSA Recurrent Spontaneous Abortion 
sHLA-G Soluble HLA-G 
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Part I:  
The immunological role of HLA-molecules on Recurrent Spontaneous Abortions– 
with special focus on HLA-E and HLA-F  
 
Introduction 
Twenty-thirty percent of all fertilizations end with spontaneous abortions in which rejection of the 
fetus before the third trimester of pregnancy occurs [1; 2; 3]. Studies indicate that up to 30-40 % 
of all pregnant women experience at least one spontaneous abortion during the first trimester 
without being aware of it [4; 3]. The underlying mechanism for these abortions is not known but 
several factors are considered pathogenic leading to premature pregnancy termination; genetic 
disorders, uterine pathologies, endocrine dysfunctions, autoimmune diseases, infectious and 
environmental factors are all thought to be implicated [Rai & Regan, 2006]. 
Recurrent spontaneous abortions (RSA) is a condition defined by 3 ≤ or more consecutive 
abortions during the first trimester of pregnancy or 3 ≤  or more during the second trimester, 
affecting 1-3 % of all couples [Carrington et al., 2005]. The etiology in some cases of RSA is 
unknown but recent research focuses on the possible involvement of polymorphisms in the 
immunologically active Human leukocyte antigen (HLA) proteins in the development of RSA in 
certain cases [Ober et al., 2003]. 
Presenting both maternal and paternal antigens the fetus is semi-allogeneic, hence a successful 
pregnancy is dependent on an altered maternal immune response [Hunt et al., 2005; Tripathi et 
al., 2006]. During pregnancy, the most prominent contact zone between the fetus and the 
maternal tissue is the placenta comprised of trophoblast cells, which are in close contact with the 
maternal immune system [Hunt et al., 2005; Sadler, 2006. The HLA class Ib proteins HLA-E, HLA-F, 
and HLA-G are all found to be expressed on the cell surface of trophoblast cells along with a low 
expression of HLA-C from HLA class Ia [Ishitani et al., 2003; Kovarts et al., 1990; King et al., 2000; 
Le Bouteiller, 2000; Hunt et al., 2005]. HLA-C, -G, and -E are found to inhibit decidual natural killer 
(NK) cell lysis of trophoblast cells [Nielsen et al., 2009]. The main research in RSA and HLA class Ib 
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has until now primarily focused on HLA-G since it has been suggested to play an important role 
during pregnancy. For example reduced concentration of soluble HLA-G (sHLA-G) has been 
suggested to increase the risk of RSA [Fuzzi et al., 2002; Pfeiffer et al., 2000; Hviid et al., 2004a; 
Hara et al., 1996; Goldman-Wohl et al., 2000; Aldrich et al., 2001; O’Brien et al., 2001; Pfeiffer et 
al., 2001; Hviid et al., 2002]. In the past years, research on the co-expressed HLA-E and HLA-F has 
though increased. HLA-E interactions are found to inhibit NK cell effector activity in the decidua 
basalis, the site of implantation, while HLA-F is suggested to influence the environment for fetal 
growth [Llano et al., 1998; Shobu et al., 2006].  
In the absence of HLA proteins the NK cell functions are activated stimulating lysis of the target 
cell which can be hypothesized to be one of the main reasons of fetal rejection during pregnancy 
[Tripathi et al., 2006]. However, the presence of HLA proteins may counteract the attack by NK 
cells, which can interact with killer inhibitory receptors (KIRs) of NK cells [Tripathi et al., 2006]. 
Together, these results indicate that HLA proteins are of important immunological interest during 
the maintenance of pregnancy. Hence, these may be implicated in the development of RSA.  
     The main focus of this study will be on the implication of HLA-E and HLA-F proteins on the 
development of RSA.  
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The semi-allogeneic fetus - an introduction  
During pregnancy, the maternal immune system adapts to the semi-allogeneic fetus preventing 
fetal rejection [Ghaffar & Nagarkatti, 2009; Wood, 2006; Janeway et al., 1999]. 
Following fertilization, the zygote which is the product of the fusion between the sperm cell 
and the egg differentiates into a blastocyst. The blastocyst consists of an inner and outer cell mass 
layer. The inner cell mass gives rise to the embryo whereas the outer cell mass gives rise to 
trophoblast cells which form the placenta. The function of the placenta is to exchange metabolic 
and gaseous products and to produce hormones essential for fetal growth. The exchange of 
oxygen and carbon dioxide is accomplished by simple diffusion whereas nutrients like amino acids, 
fatty acids, carbohydrates, and vitamins are provided through the umbilical cord [Sadler, 2006].  
Implantation of the blastocyst takes place in the endometrium, Figure 1 [Sadler, 2006; Wilcox 
et al., 1999; Dey, 2010; Seeley et al., 2008]. This implantation site is designated the decidua basalis 
[Sadler, 2006].  
Figure 1 shows the initial steps of implantation in the decidua basalis of the blastocyst [Seeley et al., 2008 - modified]. 
[9] 
 
In the decidua basalis the blatocyst penetrates the uterine epithelium [Sadler, 2006; Wilcox et 
al., 1999; Seeley et al., 2008]. During the invasion, trophoblast cells differentiate into an inner 
layer of mononucleated proliferating cytotrophoblast cells and an outer layer of multinucleated 
nondividing syncytiotrophoblast cells. Cytotrophoblast cells are also designated extravillous 
trophoblast (EVT) cells and these cells express the non-classical HLA molecules, HLA-E, -F, and -G, 
along with the classical HLA molecule HLA-C.   
Cytotrophoblast cells are located close to tissues derived from the embryo while 
syncytiotrophoblast cells invade the uterine epithelium. Syncytiotrophoblast cells are nonantigenic 
as this invasion does not stimulate an immune response [Seeley et al., 2008].  Once 
syncytiotrophoblast cells reach the maternal blood vessels they start digesting maternal venous 
capillaries forming lacunae filled and interlinked with intact maternal blood vessels as illustrated in 
Figure 2. Following, lacunae expand and merge together and are surrounded by cytotrophoblast 
cells called cytotrophoblast cords. It is through these lacunae that maternal blood circulation takes 
place [Loke & King, 1995; Seeley et al., 2008]. These cords of cytotrophoblast cells then form 
chorionic villi by protruding into the syncytiotrophoblast cells and lacunae [Loke & King, 1995; 
Seeley et al., 2008]. Further branching and expansion of these villi lead to the formation of a 
villous tree, which constitutes the placenta, Figure 3.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2 shows the two trophoblast cell populations and their position in the endometrium  
[Toth et al., 2010 - modified]. 
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The villi get in contact with maternal capillaries in the endometrium and form the uteroplacental 
circulation [Sadler, 2006]. Here the maternal and embryonic blood supplies are set apart by 
syncytiotrophoblast cells, a basement membrane, and embryonic capillary, as the 
cytotrophoblasts disappear when the placenta is mature [Loke & King, 1995; Seeley et al., 2008]. 
The trophoblast cells surrounding this placental villous tree produce hormones and are implicated 
in the transport of gasses and nutrients between the fetal circulation and maternal blood in the 
intervillous space [Pijnenborg et al., 1983]. Trophoblast cells are further responsible for the 
replacement of the maternal vessel wall ensuring an enhanced blood conductance to the 
intervillous space enabling a proper growth and development of the fetus [Pijnenborg, 1994]. An 
incomplete replacement of the maternal vessel wall can be the reason for pregnancy 
complications such as pre-eclampsia since the fetus is not provided with the required amount of 
blood supply [Brosens, 1977; Khong et al., 1986].    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From the fourth month, the placenta is composed of a fetal portion and a maternal portion 
where the maternal portion is derived from the decidua basalis. In the first trimester, the fetus 
begins to achieve immunological competence by gaining passive immunity against various 
infectious diseases [Sadler, 2006].  
Figure 3 shows the mature placenta and fetus [Seeley et al., 2008]. 
[11] 
 
Recurrent Spontaneous Abortions (RSA) 
RSA is divided into primary and secondary RSA. Primary RSA is defined as 3 ≤ consecutive losses 
and no previous successful pregnancy, whereas secondary RSA is defined as by experiencing losses 
preceeded by at least one childbirth [Toth et al., 2010].  
Several risk factors for RSA are described in Table 1. Critical factors in pregnancy are the 
implantation and the composition of placenta and the establishment of the uteroplacental 
circulation through which nutrition and gas are exchanged, all of which are highly balanced and 
intricate processes during and following fertilization. An imbalance in one or more of these 
processes might well develop into pregnancy complications.  
In unexplained RSA it is believed that normal immunomodulatory mechanisms during 
pregnancy fail, resulting in a rejection of the fetus, as response from the maternal immunesystem. 
To avoid such rejections, the leukocytes at the feto-maternal interface in the maternal immune 
system might be immunosuppressed [Loke & King, 1995]. Other risk factors are genetic disorders, 
uterine pathologies, endocrine dysfunctions, autoimmune diseases, infectious and environmental 
factors [Rai & Regan, 2006]. However, the underlying mechanisms are still unknown in nearly 50 % 
of the RSA cases [Toth et al., 2010].  
In up to 37.6 % of the RSA cases, malformation of the uterus is linked to RSA leading to late 
abortions and immature parturition [Acien, 1996]. Innate uterine anomalies have a negative effect 
on couples with RSA and are implicated in the development of RSA with a normal embryonic 
karyotype [Suqiura-Ogasawara et al., 2010]. In addition, Salim et al. [2003] found 23.8 % 
congenital uterine anomalies in women with RSA.   
Endocrinological anomalies in RSA include polycystic ovary syndrome, which affects almost 
10 % of reproductive women [Asuncion et al., 2000], thyroid dysfunction, and diabetes mellitus 
type I [Regan, 1991; Christiansen et al., 2008]. Various phospholipid antibodies can lead to RSA. 
Phospholipids are the main component of cell membranes and important in the development of 
the placenta. Therefore, phospholipid antibodies may prevent the correct development of the 
placenta and lead to abortions. However, the antibodies do not destroy the placenta but can 
damage the inner wall of blood vessels. The damage can lead to the accumulation of blood cells at 
the injury site and blood clot formation. This and constricted blood vessels may reduce blood 
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supply to the fetus and placenta and thus induce abortions or restricted growth of the fetus [Sugi 
et al., 1999; Vinatier et al., 2001]. 
     Genetic disorders in 50-60 % of RSA fetuses are associated with chromosomal anomalies. The 
most frequent is trisomy, followed by polyploidy and monosomy X [Stirrat, 1990; Stephenson et al., 
2002; Kalousek et al., 1993; Fritz et al., 2001]. These anomalies arise from first cell division of the 
egg cell. Additionally, increased chromosome anomalies from sperm cells have been reported in 
RSA patients [Giorlandino et al., 1998]. Some single gene disorders can contribute to late 
pregnancy losses like α-thalassemia [Laurino et al., 2005]. Franssen et al. [2005] have identified 
four factors in the carrier status of RSA: maternal age at secondary miscarriage, three or more 
miscarriages, a history of two or more miscarriages in a brother or sister and the same in parents.  
Unexplained RSA may be treated with immunological therapies although this is a very 
controversial issue. Paternal lymphocyte alloimmunization therapy (PLAT) is in accordance with 
some studies a way to reduce the occurrence of RSA. However, due to questionable success of 
treatment and severe side effect, PLAT is not a preferable therapy [Pandey et al., 2004; Pandey et 
al., 2005; Kano et al., 2007; Nonaka et al., 2007; Scott, 2003; Chaichian et al., 2007; Pearlman et al., 
1992; RMITG, 1994; Thorton & Bellow, 1993; Yamada et al., 1998]. Since no applicable treatment 
is available for women experiencing RSA, the elucidation of the underlying immunological and 
genetic mechanisms implicated in the development of RSA is essential in order to properly 
diagnose and treat RSA patients.   
Risk factors for the development of RSA 
Critical factors in pregnancy are the implantation and the composition of placenta and the 
establishment of the uteroplacental circulation through which nutrition and gas are exchanged, all 
of which are highly balanced and intricate processes during and following fertilization. An 
imbalance in one or more of these processes might well develop into pregnancy complications. 
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Table 1 shows a fraction of the current theories behind a successful pregnancy [Zenclussen et al., 2007 – 
modified]. 
Some of the current theories explaining the survival of the semi-allogeneic fetus within the maternal uterus 
Theory Evidence/Explanation References 
MHC expression by 
trophoblast cells is 
distinct 
The absent expression of MHC class I and II on fetal trophoblast 
cells inhibits antigen presentation. 
Expression of the non-classical HLA molecules (HLA-C, HLA-G, 
and HLA-E) by human EVT cells, antigen possibly allow:  
- that DCs display trophoblast and form antigen-specific 
Treg. 
- induction of tolerogenic DCs via immunoglobulin 
receptors. 
- NK cell inhibition. 
[Hunt et al.,1988; Hunt & 
Orr, 1992; Redline & Lu, 
1989; Zuckermann & Head, 
1986; Le Bouteiller & 
Lenfant, 1996; Gardner & 
Moffett, 2003; Sasaki et al., 
2004; Shiroishi et al., 2006; 
Chang et al., 2002; Velten et 
al., 2004] 
Decidual NK cells Decidual NK cells may be important for modifying spiral 
arteries and controlling the endometrial invasion by 
trophoblast cells. 
[Zhang et al., 2005] 
 
Suppression of T-cell 
responses 
IDO: The maternal T-cell immunity might be inhibited by fetal 
cells expressing the enzyme IDO, which metabolizes tryptophan 
due to the fact that IDO inhibition causes allogeneic fetal 
rejection. 
PDL-1: PDL-1 is an inhibitory T-cell molecule. An inhibited PDL-1 
signaling results in increased abortion rates. 
 
[Munn et al., 1998] 
 
 
[Guleria et al., 2005] 
A dominant Th2 response A Th2 response is suggested to play an important role in the 
maintenance of pregnancy, while an increased Th1 response is 
correlated with fetal rejection. 
[Lin et al., 1993] 
 
Immune tolerance 
towards paternal/fetal 
antigens 
Low levels of Treg are associated with spontaneous abortions. 
These cells are believed to be correlated with the prevention of 
autoimmunity and the development of tolerance towards 
allogeneic organ transplants.  
[Sakaguchi, 2004; 
Waldmann et al., 2004; 
Sakaguchi et al., 1995; 
Aluvihare et al., 2004; 
Zenclussen et al., 2005; 
Zenclussen et al., 2006] 
Specific suppressors of 
rejection 
LIF is believed to be required for the implantation of the 
blastocyst.  
Up-regulation of HO-1 may prevent fetal rejection. 
[Metcalfe & 
Muthukumarana, 2005; 
Stewart et al., 1992; 
Zenclussen et al., 2006] 
Innate immunity Cytokines secreted by trophoblast cells may be involved in the 
recruitment of cells of the innate immune system, which 
support pregnancy through the establishment an inflammatory 
state.  
[Abrahams et al., 2005; Fest 
et al., 2007] 
Thrombophilic disorders A balance of coagulation, fibrinolysis, and vascular remodeling 
during angiogenesis is required in order to achieve a successful 
pregnancy. An imbalance of these factors can result in the 
aggregation of surplus fibrin in the placental vessels and 
intervillous spaces. This can lead to the development of RSA. In 
fact, this condition is believed to be one of the main causes of 
RSA. Both fetal and maternal thrombophilic disorders are 
correlated with pregnancy complications.  
[Arias et al., 1998; Eldor, 
2001; Kupferminc et al., 
2000; Buchholz & Thaler, 
2003] 
Abbreviations: DC: dendritic cell, HO-1: heme oxygenase 1, IDO: indoleamine 2,3-dioxygenase, LIF: leukaemia inhibitory 
factor, MHC: major histocompatibility complex, NK cells: natural killer cells, PDL-1: programmed death ligand 1, Treg: 
regulatory T cells. 
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The Immune system 
The immune system, which constitutes the body’s defense mechanism against foreign 
microorganisms and molecules can be divided into two parts; the innate and acquired immune 
system. An elaborate balance in the immune system is crucial for the development of the fetus 
[Waller et al., 2010; Wood, 2006]. 
The innate immune system is the body’s immediate response to foreign microorganisms and 
activates the acquired immune system if it is not able to eliminate the invading microorganisms on 
its own [Waller et al., 2010; Wood, 2006]. 
Self-tolerance 
Regulatory T cells (Treg) play major roles in the development of self-tolerance. Self-tolerance is 
based upon the immune system’s ability to distinguish between the body’s own set of markers 
(self) and foreign markers (non-self), thereby preventing an immunological response towards its 
own cells. Products of the major histocompatibility complex (MHC) also called HLA are presented 
as markers on the surface of cells. Class I, comprising Ia and Ib, and class II of MHC have 
immunomodulatory functions; class Ia MHC proteins are expressed on all nucleated cells, whilst 
class Ib and class II proteins, have a restricted expression pattern [Wood, 2006; Janeway et al., 
1999]. Different patterns of MHC proteins exist on the cell surface of every cell in the body. Every 
individual carries a different set of markers, and thus has its own tissue type. In distinguishing 
between self and non-self, the immune cells of the body recognize MHC markers on the surface of 
cells. MHC proteins bind peptides which are recognized as antigens by the immune cells and even 
cells which do not express MHC proteins are recognized by the immune cells and degraded.  
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The innate immune system 
The innate immune system is based on non-specific 
mechanisms reacting quickly to inhibit or eliminate 
microorganisms whether or not the host organism has 
been exposed to these microorganisms before. The 
innate immune system consists of different components 
all involved in the elimination of invading 
microorganisms. Neutrophile granulocytes, monocytes, 
macrophages, and natural killer (NK) cells, as well as 
soluble elements such as cytokines and complement 
factors, are all parts of the innate immune system. The 
amount of receptors specific for the components of the 
innate immune system is limited in comparison to those 
for the acquired immune system. Specific molecular 
patterns shared by classes of microbes are therefore 
recognized by the innate immune system by screening 
the cell surface of foreign invaders. These patterns are 
called pathogen-associated molecular patterns (PAMP) 
which are recognized by pattern recognition receptors (PRRs). PRRs enable the recognition of 
pathogenic groups e.g. bacterial DNA, hence these receptors do not identify individual antigens 
[Bendtzen et al., 2003; Waller et al., 2010]. 
Natural killer cells of the innate immune system 
The involvement of NK cells constitutes an important factor during pregnancy, which is why we 
choose only to describe these cells of the innate immune system [Agger et al., 2005; Ishitani et al., 
2006]. Human peripheral blood NK cells are large lymphocytes with a high amount of granules in 
their cytoplasm and which do not display T cell receptors (TCRs) on their cell surface. NK cells have 
a killing function similar to that of CD8
+
 cytotoxic T cells (Tc) of the acquired immune system which 
will be discussed in the following section [Lanier, 2005]. NK cells have been found to lyse tumor 
cells as well as cells infected with viruses or intracellular microorganisms. NK cells can recognize 
 Figure 4 shows the interactions between NK 
cells, HLA class I molecules, and activating 
ligands [Lodoen & Lanier, 2005; Lanier, 2005]. 
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Figure 5 gives an overview of the humoral and cell-mediated immunity 
[General Pathology Spring, 2005]. 
and eliminate cells which do not display HLA class I molecules with antigens, see Figure 4. NK cells 
express different surface molecules reacting with different cells. When a NK cell binds to a cell 
which does not have a HLA class I protein but an activating ligand on the cell surface, the NK cell 
effector functions are activated promoting lysis of the target cell and releasing cytokines which 
modulate the adaptive immunity. The activity of NK cells binding to cells expressing HLA class I 
proteins along with peptides depends on the balance of signals [Lodoen & Lanier, 2005]. It has 
been shown that the cytotoxic activity of NK cells in the decidua basalis is decreased in 
comparison to the non-pregnant endometrium [Bulmer et al., 1991a]. NK cells are further involved 
in regulatory functions and are important components in expression of tolerance induction [Beilke 
et al., 2005; Yu et al., 2006; O’Garra & Vieira, 2004; Sakaguchi, 2005].    
Different types of NK cells with different functions and phenotypes are present in the 
endometrium and decidua basalis. These are called decidual/uterine NK cells, and consist of 
CD56
dim
, CD56
bright
, and CD16 [Loke & King, 1995; Bulmer et al., 1991b; Tabiasco et al., 2006]. NK 
cells express isoforms of neural cell adhesion molecule-1 (CD56). NK cells can be divided into two 
different cell types:  CD56
dim 
and CD56
bright
. CD56
bright
 cells secrete a higher concentration of 
cytokines after stimulation in 
comparison to the other cell type 
[Jacobs et al., 2001; Cooper et al., 
2001]. CD16 is a surface molecule also 
expressed by NK cells, which makes it 
possible for NK cells to use the 
antibody-mediated cytotoxicity 
function [Jacobs et al., 2001]. 
CD16
+
CD56
dim
 NK cells constitute about 
10-15 % of the lymphocytes, hence 
these are the main population of NK 
cells in the peripheral blood. The most 
abundant lymphocytes at the site of embryonic implantation are the CD16
-
CD56
bright
 NK cells 
constituting up to 70-80 % in the early phases of pregnancy [Lanier, 2005; Kammerer, 2005; 
Bulmer & Laash, 2005; Moffett-King, 2002; Dosiou & Giudice, 2005]. CD16
+
CD56
dim
 NK cells are 
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found in high amounts in the secretory phase of the endometrium among patients with RSA 
whereas there is a low concentration of CD16
-
CD56
bright
 NK cells indicating that these cells 
influence the maintenance of pregnancy [Lachapelle et al., 1996].  
NK cell receptors that recognize HLA class I molecules  
The maternal decidual NK cells have 
different receptors, which are bound by 
different HLA proteins, Figure 6.  
C-type lectin-like molecules (CD94/NKG2A): 
is an inhibitory receptor, which can be 
bound by the HLA-E protein bound to a 
peptide derived from e.g. HLA-G [Lee et al., 
1998; Borrego et al., 1998].  
Killer cell immunoglobulin-like receptor (KIR) 
2DL2/3 and KIR2DL1: are inhibitory 
receptors bound by HLA-C.  
CD94/NKG2C: is an activating maternal 
decidual NK cell receptor. HLA-E with bound 
peptide binds to CD94/NKG2C.  
KIR2DL4: is an activating maternal decidual 
NK cell receptor bound by HLA-G. 
KIR2DS: is an activating maternal decidual NK cell receptor i bound by HLA-C.  
Immunoglobulin-like transcript (ILT) 2 or 4: are inhibitory decidual NK cell receptors receptors 
bound by HLA-G [Bashirova et al., 2006; Allan et al., 1999; Biassoni et al., 1999; Colonna et al., 
1998; Shiroishi et al., 2003].  
The acquired immune system 
The acquired immune system has a slower response profile, gives long-term protection, and is able 
to recognize specific antigens in compared to the innate immune system. This part of the immune 
system is thought to be implicated in the maintenance of tolerance against the fetus. This defense 
system takes over after the activation of the innate immune system, and is divided into two 
Figure 6 shows both the inhibitory and stimulatory maternal 
decidual NK cells as well as the HLA molecules which bind to 
these [Moffett-King, 2002 - modified].  
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Figure 7 shows the α and β chains of 
TCR. C stands for the constant 
domains, whilst V stands for the 
variable domains [Boehmer, 2005 - 
modified]. 
interacting pathways, cell-mediated immunity and humoral immunity illustrated in Figure 5 
[Waller et al., 2010]. The following cells are components of these two pathways. 
The immunological antigen specificity and recognition is 
mediated by B and T cells due to the fact that these cells have 
clusters of antigen receptors on their cell surfaces. These 
clusters are designated clusters of differentiation (CD) 
antigens, and there are several different types of these [Waller 
et al., 2010]. B cells are important components of the humoral 
immune response. B cells produce antibodies against foreign 
antigens and differentiate into memory and plasma B cells 
[Wood, 2006; Janeway et al., 1999]. T cells of the immune 
system are able to recognize antigens in a different manner 
than B cells. There are two major types of T cells called helper 
T (Th) cells and cytotoxic T (Tc) cells. Th cells and Tc cells 
express different surface molecules designated CD4 and CD8, 
respectively. T cells have TCRs on their cell surface making it 
possible to bind HLA proteins presenting antigens. Without 
these receptors, T cells cannot recognize antigens. TCRs consists of α and β glycoprotein chains, 
which constitute the antigen-binding site as shown in Figure 7. 
Both chains consist of constant and variable domains. The latter has hyper variable regions 
which by a specific folding method constitute the antigen binding site [Agger et al., 2005; Wood, 
2006]. Not all T cells are able to recognize all antigens since their TCRs consist of different variable 
domains [Wood, 2006]. Additionally, Treg cells are thought to play an important role during 
pregnancy.  
The immune system recognizes surface molecules on cells, the majority being MHC proteins.   
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The Major Histocompatability Complex (MHC)  
In humans, MHC consists of a region of genes located on the short arm of chromosome 6 as 
illustrated in Figure 8. It contains approximately 130 expressed genes; however, not all of them 
have an immunological function [Geraghty et al., 1987]. In humans, the MHC contains the HLA 
complex.  The HLA genes are co-dominantly expressed and they have been divided into three 
classes called class I, II, and III [Wood, 2006]. The first two classes have immunological functions 
and almost all of these genes encode surface proteins [Wood, 2006]. Class I contains two subtypes, 
the classical class I HLA molecules, also designated class Ia, and the non-classical class I HLA 
molecules, or class Ib. Class Ia molecules are expressed on almost all nucleated cells of the human 
organism and this group consists of the HLA-A, -B, and -C genes, whereas class Ib consists of the 
genes HLA-E, -F, and -G [Thellin et al., 2000; Wood, 2006]. 
 
 
Figure 8 shows an illustration of the relative position of the HLA region in chromosome 6 [Mehra & 
Kaur, 2003 - modified]. 
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Class I HLA molecules consist of an α chain constituted of three α domains and a β2-
microglobulin chain, as seen in Figure 9. The β2-microglobulin chain is believed to be essential for 
the expression of HLA class I proteins on the surface of cells [Loke & King, 1995]. The two chains 
are linked to each other non-covalently. 
HLA class II is comprised of the genes DP, DM, DQ, and DR. Genes of class Ia are polymorphic, 
meaning that various alleles are expressed by these genes. The class Ib genes are oligomorphic 
since there is typically only a few alleles of the gene and they have restricted expression as they 
are expressed in few tissues [Fujii et al., 1994; Ishitani et al., 2003]. The majonity of antigens 
presented by both HLA class I and II molecules are self-antigens e.g. HLA-E binds to peptides 
derived from HLA-G. EVT cells of the placenta are the only cells in the human organism which 
express all three HLA class Ib proteins along with HLA-C [Kovarts et al., 1990; King et al., 2000; Le 
Bouteiller, 2000].  
Figure 9 illustrates the differences in the general structure of the HLA class I and II proteins.  Note that the α1 and α2 
domains are not identical between these two proteins [Wood, 2006 - modified]. 
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Interaction between the T cell receptor and Human Leukocyte Antigens (HLA) 
The α and β chains of the HLA class I surface proteins bind peptides derived from antigens, which 
are then recognized by the domains of TCRs on T cells. Only Tc cells which express CD8 molecules 
can non-covalently bind antigens presented by HLA class I molecules with their TCRs. HLA class I 
can only present intracellularly derived antigens indicating that these antigens are e.g. derived 
from viruses. In the cell, viral proteins are degraded by proteosomes into antigenic peptides which 
are then transported to the rough endoplasmatic reticulum, which is where HLA class I proteins 
are synthesized and loaded with peptide, see Figure 10. The availability of antigenic peptide 
ensures the proper association of the chains of the HLA class I protein and binding of these to the 
peptide. The antigenic peptide is bound to the specific pockets in the groove of the HLA protein. 
Afterwards, the complex is transported to the Golgi apparatus to be modified and then to the cell 
surface where it can make the recognition of the antigenic peptide by Tc cells with CD8 and TCR 
possible. This binding stimulates the release of different factors e.g. cytokines by the T cell itself 
which enhance inflammation and phagocytosis. It is noteworthy, that proteins of HLA are only 
expressed on the surface of cells when bound to antigenic peptides. HLA molecules are unstable 
without the presence of an antigenic peptide, hence these molecules will not travel to the cell 
surface to activate the immune system in these circumstances [Wood, 2006; Seeley et al., 2008; 
Rodgers & Cook, 2005].    
Figure 10 shows the intracellular 
mechanisms involved in antigenic 
peptide presentation of HLA class I 
proteins [5]. 
Figure 11 shows a simplified view of the recognition of 
MHC class I molecules on antigen presenting cells by a 
cytotoxic T cell [Andersen et al., 2006 - modified]. 
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T helper (Th) cells of the immune system recognize antigens presented on HLA class II proteins 
on the surface of antigen presenting cells. CD4
+
 Th cells have high affinity for HLA class II peptides 
on antigen presenting cells whereas CD8
+
 Tc cells have a high affinity for peptides bound to the 
cleft of the HLA class I proteins on all nucleated cells [Waller et al., 2010]. HLA allelic variation and 
polymorphism are of great importance for antigen binding and stimulation of T cells both in vitro 
and in vivo [Bettinotti et al., 1998; Rivoltini et al., 1996]. Gene products of HLA polymorphic alleles 
stimulate different T cells underlying the importance of gene variations for up- and 
downregulation of the T cell-mediated cytotoxicity. T cells have MHC-restricted recognition of 
antigens because an individual T cell can only recognize specific antigens bound to specific HLA 
proteins, Figure 11 [Wood, 2006; Rodgers & Cook, 2005]. 
Th1/Th2-Mediated Tolerance 
Antigens which are recognized by CD4
+
 Th cells via HLA class II activate either the Th1 (cell-
mediated immunity) or Th2 (antibody-mediated immunity) subset of cells which are distinguished 
by their cytokine production, see Figure 12. These responses stimulate CD8
+
 Tc cells, B cells, 
assemble neutrophiles of the innate immune system, or stimulate the phagocytic activity of 
macrophages [Waller et al., 2010].  
 
 
 
The two Th lymphocyte responses have different functions and they regulate each other 
thereby ensuring a balance in the organism, whereas extracellular antigens stimulate the 
differentiation of Th2 cells [Waller et al., 2010; Janeway et al., 1999; Lillevang & Møller, 2002]. In 
Figure 12 shows how the two cell responses regulate each other [Bushell & Wood, 1999].  
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the Th1 response, cytokines activate macrophages, dendritic cells, and neutrophile granulocytes, 
thereby inducing phagocytosis. Hence, the Th1 has a central role in inflammatory reactions. Th2 
cells inhibit macrophages and ensure the production of antibodies by stimulating B cells [Lillevang 
& Møller, 2002; Chaouat et al., 2004].  
Cytokines involved in the development of tolerance  
Cytokines which are secreted in the decidua basalis have an important function correlated with a 
healthy pregnancy since these molecules are involved with the immune system, angiogenesis, and 
vascular development [Ashkar et al., 2000; Bulla et al., 2003]. T cells, NK cells, as well as dendritic 
cells all secrete cytokines affecting either the humoral or cell-mediated immunity [Whiteside, 
1994]. NK cells produce cytokines such as IFN-γ which stimulates the Th1 response [Loza & 
Perussia, 2001].  
Interleukin-2 (IL-2) is a cytokine, which can bind to receptors on NK cells enhancing the 
efficiency of the cytotoxic function of these cells. These NK cells also have specific receptors, which 
are able to bind HLA class I molecules presented on normal cells. When NK cells bind to these 
normal cells which do not have activating ligands on their cell surface, an inhibiting effect is 
observed leading to the inactivation of the NK cell preventing the lysis of the normal cell [Agger et 
al., 2005; Moretta & Moretta, 2004]. Other cytokines like TNF-α, IL-3, IL-5, IL-10, and IL-13 are also 
secreted by NK cells, thus stimulating the Th2 response [Cooper et al., 2001; Grant et al., 2008; 
Cuturi et al., 1989; Loza et al., 2002]. Thus, a fine balance of NK cell stimulation and inhibition is 
important for pregnancy. There is also some indication that the KIR genes may influence RSA [Hiby 
et al., 2008; Faridi et al., 2009].    
Th2 mediated response in pregnancy 
The Th2 response is implicated in a successful pregnancy, and some studies show that an 
imbalance of the Th1 and Th2 responses might be prevalent in pregnancy complications such as 
RSA and pre-eclampsia [Chaouat et al., 2004]. The shift of the Th2 response to the Th1 response is 
a possible effect of miscarriages, however it can also be a cause of the condition [Christiansen et 
al., 2005]. Women experiencing RSA with chromosomal anomalies are shown to have decreased 
amount of Th2 cells in the decidua basalis whereas the concentration of Th2 cells is not affected in 
women having abnormal chromosomes [Michimata et al., 2003]. A pro-inflammatory 
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microenvironment and Th1 response shifted to Th2 seem to ensure a successful pregnancy during 
the early phases of pregnancy due to the fact that the Th2 response controls endocrine and 
immune interactions [Fest et al., 2000; Clark et al., 2002; Chaouat et al., 2004]. Furthermore, 
progesterone which is found in higher concentrations in the plasma of pregnant women is 
indicated to activate the Th2 response, thereby reducing cytokines of the Th1 response and 
suppressing the immunological response against the fetus, thus protecting the fetus [Miayaura & 
Iwata, 2002; Beagley & Gockel, 2003].  Wegman et al. [1993] have shown in a study conducted on 
mice that the Th2 response is present in normal pregnancy. They have furthermore reported that 
the Th1 response can stimulate fetal rejection thus promoting a miscarriage.  In another study 
conducted by Michimata et al. [2003], the occurrence of RSA was correlated with a reduced 
amount of Th2 cells at the implantation site in patients having normal chromosomal content. 
However, patients with abnormal chromosomal content did not show to have a decreased level of 
Th2 cells.  
A more complex system is believed to be implicated in pregnancy and tolerance towards the 
fetus rather than the quite simple Th1/Th2 model. This system is designated the 
Th1/Th2/Th3/Treg1 paradigm. Regulatory T 1 cells (Treg1) are CD4
+
 T cells stimulated by IL-10 and 
these cells secrete IL-10, IL-2, and IL-4. This cytokine pattern has an impact on other T cells 
suppressing antigen-induced stimulation of other CD4
+
 T cells, hence Treg1 cells are important in 
the regulation of the immune system. T helper 3 (Th3) cells encompass unique cells secreting 
mainly transforming growth factor (TGF)-β when being stimulated by antigens. This cell subset 
may also have immunosuppressive effects [Janeway et al., 1999; O’Garra & Vieira, 2004]. 
Furthermore, TGF- β1 is indicated to stimulate the growth and proliferation of placental cells 
[Ingman & Robertson, 2002]. TGF-β1 is also associated with an increase in fetal and placental 
weight in animal studies. Sakaguchi [2005] has reported that Treg1 cells are implicated in 
immunological self-tolerance, which is why both Treg1 and Th3 cells might be involved in RSA. 
However, more research is required. These findings support the important role of TGF, Th3 cells, 
and Treg1 cells during pregnancy [Robertson, 2002; Sakaguchi, 2005].     
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Table 2 gives an overview of the cytokine production of the two Th cells, which cytokines they are 
stimulated by as well as the function of the T cells.  
T cell Stimulated by the 
cytokines 
Secreted cytokines Function References 
Th1 IFN-α 
IL-12 
IFN-γ 
IL-2 
IL-3 
TNF-α  
TNF-β 
GM-CSF 
Cell-
mediated 
immunity. 
Lillevang & Møller, 
2002; Theofilopoulos et 
al.,  
2001; Wood, 2006. 
Th2 IL-4 IL-3 
IL-4 
IL-5 
IL-6 
IL-9 
IL-10 
IL-13 
GM-CSF 
TNF-α 
Antibody 
(humoral)-
mediated 
immunity. 
Lillevang & Møller, 
2002; Theofilopoulos et 
al.,  
2001; Wood, 2006. 
IFN: Interferon, IL: interleukin, TNF: tumor necrosis factor, GM-CSF: Granulocyte-macrophage 
colony-stimulating factor. 
 
Tolerance against the semi-allogeneic fetus is correlated with the Th1/Th2 
response 
During successful pregnancy, an immunological shift from Th1 to Th2-response is hypothesized. 
Progesterone is suggested to promote this switch at the feto-maternal interface but HLA-G may 
also be involved. Progesterone promotes the differentiation of Th2 cells, and thus acts 
immunosuppressive [Szekeres-Bartho, 1992; Wilson, 2004; Piccinni et al., 2000]. The difference in 
cytokine secretion in the Th1 and Th2 responses is believed to play a key role in fetal growth 
during pregnancy [Wegmann et al., 1993]. Trophoblast cells have been shown to produce IL-4, a 
Th2-type cytokine known to affect the humoral immunity [Sacks et al., 2001; Wood, 2006]. The 
Th2-mediated response controls endocrine and immune interactions, and is thus implicated in a 
successful pregnancy [Fest et al., 2000; Clark et al., 2002; Chaouat et al., 2004]. Some Th1-type 
cytokines have proven to be toxic towards the embryo. Hill et al. [1995] have studied trophoblast-
activated peripheral blood mononuclear cells in women with RSA and fertile controls. Women 
with RSA were positive for TNF-α, TNF-β, and IFN-γ which are all Th1 cytokines. In contrast to this, 
[26] 
 
fertile women were tested positive for the occurrence of the Th2 cytokines, IL-10 and IL-4 [Hill et 
al., 1995].  
Trophoblast cells are believed to be lysed as a response to NK cells releasing IFN-γ thereby 
stimulating macrophages, which phagocytize trophoblast cells. Hence, Th1-mediated immune 
damage is stimulated [Baines et al., 1997; Haddad et al., 1997].  Furthermore, it is suggested that 
cytokines secreted by Th1 cells enable the conversion of NK cells into lymphokine-activated killer 
cells, which have the potential of lysing trophoblast cells [Raghupathy, 2001]. Apoptosis of 
trophoblast cells may also be stimulated by IFN-γ, which is a Th1 cytokine and TNF-α which is 
secreted by both Th1 and Th2 cells [Yui et al., 1994]. Since the cytokines produced by Th2 cells 
stimulate the humoral immune system, whilst Th1 cells stimulate the cell-mediated immunity, an 
imbalance of the Th1/Th2 response may be implicated in pregnancy complications such as RSA 
[Chaouat et al., 2004]. Hence, a Th2 response is believed to be important in order to achieve a 
successful pregnancy [Raghupathy, 1997].  
HLA class Ia genes 
The classical HLA genes are composed of HLA-A, -B, and - C. These genes are highly polymorphic 
[Statsny, 2002]. Most of the polymorphisms are non-synonymous. Proteins encoded by these 
genes present peptides formed in the cytosol to CD8
+
 T cells. Studies suggest that these proteins 
bind to the stimulating receptor NKG2C, see Figure 6 and thus regulate NK cell and CD8
+
 Tc cell 
functions [Cerwenka & Lanier, 2001]. HLA-C proteins might be implicated in the stimulation and 
inhibition of decidual NK cells on trophoblast cells [Nielsen et al., 2009]. The classical HLA genes 
are also involved in the rejection of transplants [Ghaffar & Nagarkatti, 2009]. The HLA-A and HLA-B 
proteins do probably not play key roles during pregnancy due to the absence of cell surface 
expression of these in trophoblast cells. Hence, the HLA class Ib genes are the main focus of this 
report.  
HLA class Ib genes 
A description of the three HLA class Ib genes will be given in the following sections. The HLA class 
Ib genes are as previously mentioned composed of HLA-E, -F, and -G. These genes are not as highly 
polymorphic as the HLA class Ia and class II genes. HLA-G and HLA-E have peptides as ligands and 
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all three gene products of HLA class Ib have specific NK cell receptors, see Figure 6 [Rodgers & Cook, 
2005]. The proteins encoded by these genes show a restricted set of antigens [Janeway et al., 
1999]. HLA class Ia and Ib genes have related structures, however differences exist mainly at the 3’ 
end, also designated the cytoplasmic tail of the genes [Geraghty et al., 1987; Heinrichs & Orr, 
1990]. HLA proteins contain eight to nine amino acids in their binding pocket, in which bound 
peptides are presented to T cells. Studies indicate that the non-classical HLA genes are involved in 
the suppression of the immune system as well as being key components in the development of 
long-term tolerance [Carosella et al., 1999; Ishitani et al., 2003; LeMaoult et al., 2004].       
HLA-G   
The best studied gene of the HLA class Ib genes is HLA-G. This gene is expressed in the placenta by 
fetal trophoblast cells, thymus, cornea, nail matrix, by thymic endothelial cells, dendritic cells, and 
T cells [Ishitani et al., 2003; Le Rond et al., 2004; Le Friec et al., 2004; Carosella et al., 2003; Le 
Discorde et al., 2003; Ito et al., 2005]. Since HLA-G mRNA is alternatively spliced, several isoforms 
of the gene product are obtained. Hence, there are both soluble and membrane-bound forms of 
the HLA-G protein [Geraghty et al., 1987; Ishitani & Geraghty, 1992; Fujii et al., 1994; Kirszenbaum 
et al., 1995; Hviid et al., 1998; Paul et al., 2000; Ishitani et al., 2006]. HLA-G consists of eight exons, 
however as a result of a nonsense codon, exon seven and eight are not translated [Rousseau et al., 
2003; Hviid et al., 2003]. Thus, the HLA-G gene has a truncated cytoplasmic tail [Loke & King, 1995]. 
HLA-G has been found on trophoblast cells implicating the role of HLA-G as an important factor for 
feto-maternal interactions and the successful outcome of pregnancy. The interaction between 
HLA-G and receptors on immune cells is believed to be one of the mechanisms behind the 
development of tolerance [Le Gal et al., 1999; Rouas-Freiss et al., 1997]. Additionally, it seems that 
the expression of HLA-G may influence the acceptance of heart, kidney, and liver transplantations 
[Carosella et al., 1999; Ishitani et al., 2003].  
Several polymorphisms of HLA-G have been determined in the 5’ upstream regulatory region 
(URR) and 3’ untranslated region (UTR), which seem to have functional impacts on the expression 
of the gene. Fifteen alleles of HLA-G at the protein level are discovered. The polymorphisms found 
in HLA-G are not located in the binding groove of the protein, hence they do not affect the ability 
of HLA-G to bind peptides [Marsh et al., 2002; Harrison et al., 1993; Hviid et al., 1999, 2003]. One 
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intriguing polymorphism is a 14 bp insertion/deletion polymorphism (5’-ATTTGTTCATGCCT-3’) 
found in exon 8 at position 3741 of HLA-G [Geraghty et al., 1987]. This polymorphism is to be 
found both in the HLA-G gene as well as in the transcript [Harrison et al., 1993], and is believed to 
be associated with the HLA-G mRNA stability [Loke & King, 1995]. Even though 5’ URR and 3’ UTR 
are not translated, these regions have regulatory functions relevant for the expression of HLA-G¸ 
hence the possible important role of the 14 bp insertion/deletion polymorphism [Hviid, 2006(a); 
Harrison et al., 1993; Hviid et al., 1999]. The allele frequency of the 14 bp polymorphism sequence 
is nearly equal in Caucasian populations, this is, however, not the case in African populations, 
where the deletion dominates [Hviid, 2006(a); Harrison et al., 1993]. The 14 bp insertion 
polymorphism is correlated with reduced concentrations of HLA-G mRNA, and with reduced 
concentration of sHLA-G in serum and plasma [Hviid et al., 2003; O’Brien et al., 2001; Rousseau et 
al., 2003; Rizzo et al., 2005]. The reduced level of sHLA-G protein in the decidua basalis and plasma 
may be involved in a reduced implantation rate after in vitro fertilization [Fuzzi et al., 2002; 
Pfeiffer et al., 2000; Hviid et al., 2004a]. There is, however, contradictory studies regarding the 
impact of this polymorphism and its influence on pregnancy complications [Iversen et al., 2008].  
The short cytoplasmic tail of HLA-G enables this protein to be expressed on the cell surface. 
There are several peptides, which are ligands for HLA class Ib molecules, however, only few are 
able to be anchored in the hydrophobic binding groove of HLA-G due to its specificity and low 
polymorphism [Rodgers & Cook, 2005; Marsh et al., 2002]. 
As previously mentioned, the HLA-G protein binds to following two types of decidual NK cell 
receptors: ILT2 or 4, which are inhibitory receptors, and KIR2DL4 which are activating receptors. 
An interaction between HLA-G and the inhibitory receptors can suppress NK cells [Bashirova et al., 
2006; Allan et al., 1999; Biassoni et al., 1999; Colonna et al., 1998; Shiroishi et al., 2003]. Also, Tc 
cell function and CD4
+
 T cell proliferation are inhibited by the HLA-G protein, hence the role of 
HLA-G as an immunosuppressant [Le Gal et al., 1999; LeMaoult et al., 2004]. The isoform of sHLA-
G has been implicated in inducing apoptosis of CD8
+
 T cells [Fournel et al., 2000; Contini et al., 
2003]. The tissue where HLA-G is mainly expressed is decidua basalis by EVT cells. By interacting 
with the mentioned receptors on maternal decidual NK cells in the decidua basalis, HLA-G 
prevents an immune response towards these trophoblast cells [Goldman-Wohl et al., 2000; Kovats 
et al., 1990; Rouas-Freiss et al., 1997].  
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Thus, HLA-G is believed to be an important factor in certain pregnancy complications such as 
RSA and pre-eclampsia [Hara et al., 1996; Goldman-Wohl et al., 2000; Aldrich et al., 2001; O’Brien 
et al., 2001; Pfeiffer et al., 2001; Hviid et al., 2002; Hylenius et al., 2004; Yie et al., 2004]. HLA-G 
might be a key protein in the shift of the proinflammatory Th1 response to Th2, which is as 
previously mentioned essential for a successful pregnancy [Chaouat et al., 2004]. In addition, 
methylation of HLA-G and expression of sHLA-G may also be implicated in RSA [Ober et al., 2003; 
Hviid et al., 2004(b)]. Low concentrations of HLA-G are found in patients with pre-eclampsia which 
indicates that an adequate level of HLA-G expressed by EVT cells is important during pregnancy 
[Colbern et al., 1994; Goldman-Wohl et al., 2000; Hara et al., 1996; Lim et al., 1997]. Some studies 
indicate that the risk of developing RSA is higher among women being homozygous for the HLA-G 
14 bp insertion polymorphism in comparison to women who are heterozygous [Moreauv et al., 
2008]. The plasma concentration of sHLA-G is also lower among the +14 bp homozygous women in 
comparison with women with the two other 14 bp HLA-G genotypes [Hviid et al., 2004a: Hviid et 
al., 2004b; Chen et al., 2008]. However, in order to fully determine the function of HLA-G, more 
research is required.  
HLA-E 
HLA-E is presented on the surface of all cells and tissues that express classical HLA class I proteins. 
It is also expressed on placental cells, which are the only cells where simultaneous expression of 
HLA-C, HLA-G, HLA-F, and HLA-E is observed [Ishitani et al., 2003; Lee et al., 1998]. 
HLA-E is the least polymorphic of the HLA class I genes having in total nine alleles five of them 
being referred to as E*0101, E*0102, E*010301, E*010302 and E*0104 in accordance with the 
former nomenclature. These polymorphisms correspond to the new nomenclatures as following 
E*0101 = E*01:01:01:01, E*010301 = E*02:03:01:01, E*010302 = E*02:03:01:02 and E*0104 = 
E*01:04. In the following, the new nomenclature of the alleles will be used. E*0102 is not listed as 
it doesent present amino acid changes. E*01:03:01:01 and E*01:03:01:02 are in some research 
papers described as one allele, E01:03:01:01, since only a synonymous substitution distinguishes 
these two alleles. Hence the same gene product is obtained [Tripathi et al., 2006; Ishitani et al., 
2006; Rodgers & Cook, 2005]. Nearly equal frequencies of E*01:03:01:01 and E*01:03:01:02 are 
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found in diverse populations. These five polymorphisms can be categorized as three non-
synonymous and one synonymous substitution in the coding region, Table 3 [Tripathi et al., 2006]. 
Three of the mentioned alleles of HLA-E, E*01:01:01:01, E*01:03:01:01, and E*01:03:01:02, 
have an impact on the protein products.  
Amino acid position: 77 107 150 157 211 
E*01:01:01:01 AAC – Asn AGG - Arg GCC – Ala  AGA - Arg  GCG – Ala 
E*01:03:01:01   GGG – Gly       
E*01:03:01:02   GGG – Gly       
E*01:03:02 AAT – Asn GGG – Gly        
E*01:03:03 AAT – Asn  GGG – Gly  GCT – Ala      
E*01:03:04 AAT – Asn GGG – Gly      GCA - Ala 
E*01:04   GGG – Gly     GGA - Gly   
Table 3 shows seven of the in total nine HLA-E alleles, which have no differences at the protein level. The bold codons 
indicate non-synonymous polymorphisms, whereas the unmarked codons represent synonymous polymorphisms [6]. 
The changes in gene products as shown in Table 3 cause a difference in the affinity of HLA-E for 
antigenic peptides. E*01:03 (E
G
) contains a glycine residue at position 107 which is the same as 
most of the HLA class I molecules. E*01:01:01:01 (E
R
) contains an arginine residue at the same 
position as E
G
. It has been demonstrated that the amino acid residue at position 107 may not 
directly influence antigen presentation; however the polymorphism may have an impact on the 
binding affinity for the TCR [Tripathi et al., 2006]. The difference in the affinity of the peptides is 
10- to 100-fold higher for E
G
 than E
R
 giving rise to a higher expression of E
G
 on the cell surface in 
comparison to E
R
 [Rodgers & Cook, 2005]. It has been shown that there are differences between 
the binding affinities for peptides in the two allelic forms, E
G
 and E
R
. This could be due to variations 
in the thermal stabilities of the alleles. Furthermore, it may have an influence on the relative 
concentrations of HLA-E on the cell surface which might affect the inhibitory activity [Ishitani et al., 
2006]. 
The structure of HLA-E is similar to the other HLA class Ia molecules and the binding pocket of 
HLA-E consists of hydrophobic amino acids making the binding affinity of HLA-E to peptides 
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derived from HLA-G and HLA class Ia higher. The hydrophobic properties of HLA-E restricts the 
selection of peptides that can bind HLA-E [O’Callaghan & Bell, 1998].    
Several studies have shown that HLA-E can only bind peptides from other HLA class I signal 
sequences especially HLA-G and HLA-E is only expressed on the surface of cells if such a binding 
occurs, hence HLA-E is regulated by the other HLA class I molecules [Lee & Geraghty, 1996; Lee et 
al., 1998; Braud et al., 1998].  Binding of specific antigenic peptides to HLA-E is dependent on a 
functional transporter associated with antigen processing (TAP) heterodimer. Surface levels of 
HLA-E have been shown to affect the inhibitory activity of NK cells [Lee et al., 1998]. HLA-E 
constitutes a complex when bound to peptides from other HLA class I proteins and such a complex 
interacts with CD94/NKG2A, which is a receptor located on maternal decidual NK cells thereby 
inhibiting the cytotoxic function of NK cells. When the HLA-E/antigen complex has bound to the 
CD94/NKG2 receptor, the cytotoxic activity of NK cells is inhibited [Lee et al., 1998; Borrego et al., 
1998]. Furthermore, it has been demonstrated that the inhibitory receptor CD94/NKG2A has a 
higher binding affinity for the HLA-E/peptide complex in comparison to the activating receptor 
CD94/NKG2C dependent on the peptide sequence [Llano et al., 1998; Vales-Gomez et al., 1999;  
 Lee et al., 1998].The HLA-E/CD94/NKG2A interactions are found in the decidua basalis during 
pregnancy indicating that these interactions are important during pregnancy [Llano et al., 1998]. 
HLA-F 
 HLA-F is like HLA-G and HLA-E also part of the non-classical genes with only a few published 
studies. Geraghty et al. [1990] was the first to identify this gene and they proposed that it was 
expressed as a β2-microglobulin-associated protein of 40-41 kDa. They discovered that the HLA-F 
protein is shorter than the typical HLA class I proteins because of a missing exon 7 in comparison 
to the two other HLA class Ib genes. The lack of exon 7 produces a protein with a shortened 
cytoplasmic domain. An in situ study shows that HLA-F is expressed in the tonsil, spleen and 
thymus tissue but no surface expression is detected in this study [Lepin et al., 2000]. 
HLA-F has a low degree of polymorphism [Moscoso et al., 2006; Geraghty et al., 1992]. The 
level of polymorphism is very small compared to the class Ia molecules. At the transcriptional 
level, HLA-F generally has a similar pattern of expression as the class Ia genes [O’Callaghan & Bell, 
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1998]. HLA-F has 21 alleles, which are listed in Table 4 along with their locations. The HLA-F protein 
consists of three domains; α1, α2, and α3, like the other HLA class I proteins [Moscoso et al., 2006]. 
Table 4 shows 14 HLA-F alleles out of the total of 21, which have no differences at the protein level. The bold codons 
indicate non-synonymous polymorphisms whereas the unmarked codons represent synonymous polymorphisms [7]. 
HLA-F alleles Codon -9 Codon -1 Codon 50 Codon 251 Codon 329 
F*01:01:01:01 GCC - Ala GCG - Ala CCG - Pro TCT - Ser GCC - Ala 
F*01:01:02:01  GCA - Ala    
F*01:01:02:02  GCA - Ala    
F*01:01:02:03  GCA - Ala    
F*01:01:02:04  GCA - Ala    
F*01:01:02:05  GCA - Ala    
F*01:01:03:01     GCT - Ala 
F*01:01:03:02     GCT - Ala 
F*01:01:03:03     GCT - Ala 
F*01:01:03:04     GCT - Ala 
F*01:02 GTC - Val    GCT - Ala 
F*01:03:01:01    CCT - Pro  
F*01:03:01:02    CCT - Pro  
F*01:04   CAG- Gln  GCT - Ala 
Lepin et al. [2000] found a direct molecular interaction of recombinant HLA-F tetramers with 
the inhibitory receptors ILT2 and ILT4 receptors at the cell surface. To demonstrate this, they 
stained peripheral blood monocytes and B cells from healthy individuals with recombinant HLA-F 
tetramers. After this, they have studied whether or not HLA-F tetramers could bind cells which 
were transfected with ILT receptors. Here, they found that the HLA-F tetramer bind cells 
presenting ILT2 and ILT4 demonstrating a direct molecular interaction of HLA-F with ILT2 and ILT4.  
Ishitani et al. [2006] argues that this interaction in vivo is questionable because all HLA class I 
proteins have a similar interaction in their α3 domain.  
To localize the expression of HLA-F in the body different research groups have designed anti-
HLA-F monoclonal antibodies. Wainwright et al. [2000] have designed antibodies that were 
directed against synthetic peptides which are similar to the α1 domain of HLA-F. By this method, 
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they found that HLA-F was only present in the cytoplasm of peripheral blood B cells, as well as in B 
cell lines, and tissues where B cells are found. They did not observe any cell surface expression of 
HLA-F which indicates that this protein does not bind peptides. This gave rise to speculation that 
HLA-F is expressed as an empty heterodimer devoid of peptide. This result is contradictory to the 
findings of Lepin et al. [2000] whose results imply that HLA-F forms a complex with TAP, thereby 
indicating the possible ability of HLA-F to bind peptides. Wainwright et al. [2000] also found that 
treatment with IFN-γ induces the translation of HLA-F, however this does not necessarily result in 
cell surface expression.  
Ishitani et al. [2003] was the first to demonstrate surface expression of HLA-F in vivo. Like the 
two other groups they produced anti-HLA-F monoclonal antibodies, but by using refolded HLA-F 
protein in order to examine the expression of HLA-F in normal cells and cell lines [Lee & Geraghty, 
2003]. Ishitani et al. [2003] have obtained results similar to the two former studies, however they 
found surface expression on Epstein-Barr Virus (EBV)-transformed lymphoblastoid cell lines and 
some monocyte cell lines in contrast to Lepin et al. [2000] who did not find any surface expression 
in situ. Hence, it is still uncertain whether or not HLA-F binds peptides [Ishitani et al., 2006]. 
HLA class II genes 
DP, DM, DQ, and DR genes belong to HLA class II and are just like the HLA class Ia genes highly 
polymorphic. These genes have a restrictive expression profile, and they are expressed mostly on 
leukocytes presenting antigens to Th cells [Sell et al., 1996]. HLA class II proteins consist of an α-
chain with two domains and a β-chain with two domains as well. These two chains are linked to 
each other non-covalently. Both the α and β- chains possess transmembrane regions as well as 
cytoplasmic tails in contrast to HLA class I proteins [Wood, 2006]. The HLA class II proteins present 
exogenous antigenic peptides to CD4
+
 Th cells where these peptides are degraded in intracellular 
membrane-bound vesicles. Hence, HLA class II proteins present peptides originated from 
pathogens which are living in macrophage vesicles or are taken up by endocytosis by phagocytic 
cells or B cells [Janeway et al., 1999]. HLA class II proteins with bound peptides are recognized by 
either the Th1 or Th2 cells [Janeway et al., 1999]. Dependent on which Th cells are activated, a 
cell- or antibody-mediated response is stimulated. Since the HLA class II genes are involved in 
antigenic peptide presentation, these genes are also associated with organ transplantation, and 
[34] 
 
autoimmune diseases [Svejgaard et al., 1983; Kumar et al., 2009]. HLA class II genes may also be 
implicated in the development of RSA [Janeway et al., 1999; Nielsen et al., 2009].  
The role of HLA-E and -F in pregnancy and Recurrent Spontaneous Abortions 
HLA-E 
HLA-E constitutes an important role in feto-maternal cellular interactions through two types of 
pathways. Similar to both pathways is the binding of HLA-E to a nonamer peptide which is 
essential for recognition by two different types of cells [Ishitani et al., 2006].  
Originally, HLA-E was found not to be expressed on the cell surface. Later research discovered 
the requirement of HLA-E/peptide complex for cell surface expression on EVT cells. HLA-E binds to 
peptides derived from HLA class I molecules as described previously. HLA-E/peptide complexes are 
ligands of a subset of NK-receptors among which are CD94/NKG2A and KIR-mediated recognition. 
Binding of the complex to the receptor induces inhibition of NK cells, thus this high affinity 
interaction is believed to play a role in the protection of the fetus from a maternal immune 
response during pregnancy [Tripathi et al., 2006; Ishitani et al., 2006].  
Other studies demonstrate the binding of HLA-E to peptides other than those derived from HLA 
class I molecules. Falk et al. [2002] and Llano et al. [1998] have found that HLA-E surface 
expression was also induced by binding of Human Cytomegalovirus (HCMV) glycoprotein. Ulbrecht 
et al. [1998] have demonstrated the binding of HLA-E cells infected by EBV and influenza virus 
suggesting alternative pathways than CD94/NKG2A-mediated recognition of HLA-E/HLA class I 
molecules complex. HLA-E bound to peptides derived from EBV, HCMV, or HLA class Ia signal 
sequences induces the activity of CD8
+
 Tc cells through interaction with TCR [Romagnani et al., 
2002 ; Pietra et al., 2003]. In addition to TCRs, CD8
+
 Tc cells were also found to express inhibitory 
NK-receptors. Binding of HLA class I proteins to inhibitory NK receptors inhibits the TCR-induced 
activation [Ishitani et al., 2006].  
Tripathi et al. [2006] have studied a possible association of HLA-E polymorphism in women with 
primary RSA in comparison to fertile women. The patients were north Indian women with primary 
RSA. Furthermore, they had been investigated for other possible causes for RSA. The five known 
alleles of HLA-E at the time were studied; E*0101, E*0102, E*010301, E*010302 and E*0104 (In 
Table 3 listed according to the new nomenclature). Studies were performed on exons 2 and 3 
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[Tripathi et al., 2006]. Polymorphism at codon 82/83 and codon 157 were studied through 
restriction fragment length polymorphism, whereas polymorphisms at codon 77 and 107 were 
studied by amplification refractory mutation system PCR. Three out of the five alleles were 
confirmed in both patients with RSA and fertile controls; E*0101 (E
R
), E*010301, and E*010302 
(E
G
), as seen in Table 5. E
R
 homozygotes were found to be significantly higher in patients with RSA, 
suggesting that this allele might play an important role during pregnancy [Tripathi et al., 2006].   
Table 5 shows the genotypic distribution of HLA-alleles in the study by Tripathi et al. [2006]. 
a
χ
2
=6.207; P=0.0127. 
HLA-E alleles RSA patients (%) Controls (%) 
01:01:01:01/01:01:01:01 59 (49.16)
a 
40 (30.33)
a 
01:01:01:01/01:03:01:01 (01:03:01:02) 16 (13.33) 23 (19.16) 
01:01:01:01/01:03:02 35 (29.16) 45 (37.50) 
01:03:01:01 (01:03:01:02)/01:03:01:01 (01:03:01:02) 2 (1.66) 2 (1.66) 
01:03:01:01 (01:03:01:02)/01:03:02 8 (6.66) 6 (5) 
01:03:02/01:03:02 0 (0) 4 (3.33) 
Total 120 (100) 120 (100) 
Another study conducted by Steffensen et al. [1998], which was based on studies performed on 
exon 2 and 3 on samples from Danish women having experienced at least five abortions showed 
an equal distribution of the two alleles, E
G
 and E
R
,
 between patients with RSA and fertile controls 
[Steffensen et al., 1998]. Another study done by Kanai et al. [2001] supported the study done by 
Steffensen et al. [1998] as no difference in the distribution between the two alleles E
G
 and E
R
 was 
found. The study was based on samples from women who had experienced at least three 
unexplained abortions and a possible association with RSA for both homozygotes and 
heterozygotes was examined. The genotype frequencies obtained in this study are given in Table 
6. Kanai et al. [2001] found no specific differences in the distribution pattern for the HLA-E alleles 
between Japanese RSA patients and fertile women implying that HLA-E polymorphisms in the 
coding region of the gene does not play a central role in RSA [Kanai et al., 2001]. 
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Table 6 shows HLA-E genotype and allele frequencies in 30 couples with RSA compared to 38 couples with 
normal pregnancy [Kanai et al., 2001]. 
Genotype 
frequency 
Female (RSA) 
(n=30) 
 
Male (RSA) 
(n=30) 
Female (normal) 
(n=38) 
 
Male (normal) 
(n=38) 
E
G 
107 66.7 % 66.7 % 67.1 % 71.3 % 
E
R 
107 33.3 % 33.3 % 32.9 % 23.7 % 
E
G
/E
G
 12 (40 %) 13 (43.3 %) 17 (44.7 %) 23 (60.5 %) 
E
G
/E
R
 16 (53.3 %) 14 (46.7 %) 17 (44.7 %) 12 (31.6 %) 
 E
R
/E
R
 2 (6.7 %) 3 (10 %) 4 (10.5 %) 3 (7.9 %) 
 
Strong et al. [2003] showed a higher frequency of E
R 
in RSA patients supporting the results 
obtained by Tripathi et al. [2006]. 
These results suggest that the importance of polymorphisms in HLA-E during pregnancy is 
controversial and might be dependent on both geoethnicity and selection criteria for RSA patients 
and fertile controls. Studies have been made supporting the occurrence of a higher frequency of 
E
G
 in Chinese populations, and an equal distribution of the alleles in Caucasian, African-American, 
and Hispanic people [Kanai et al., 2001; Grimsley and Ober, 1997; Tripathi et al., 2006; Gomez-
Casado et al., 1997]. Furthermore, the frequency of E
G
 has been shown to correlate with RSA 
patients in Chinese couples [Grimsley & Ober, 1997]. Another possibility concerning the 
association of HLA-E polymorphisms and the development of RSA could be that alterations in 
another part of the gene than the studied exon 2 and 3 may influence the development of RSA.  
HLA-F 
The function of HLA-F is suggested to influence the environment for fetal growth during pregnancy 
as its expression on the cell surface of EVT cells increases from the second trimester of pregnancy 
and throughout the rest of the pregnancy [Shobu et al., 2006]. 
HLA-F has been found to interact with TAP implying that HLA-F is able to bind peptides derived 
from TAP even though surface expression is not associated with the presence of TAP [Lepin et al., 
2000; Lee & Geraghty, 2003]. Expression of HLA-F on the surface of EBV transformed cells 
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supports the theory that HLA-F plays an important role in feto-maternal interactions and that the 
restricted surface expression is due to ligand specificity [Shobu et al., 2006]. A possible ligand may 
be a pathogen-derived peptide [Lepin et al., 2000]. Underlining this theory, Lee & Geraghty [2003] 
have demonstrated HLA-F expression on EBV transformed cells in contrast to no detectable 
surface expression on normal EVTs. 
HLA-F is known to associate with β2-microglobulin but no binding of peptide for the rest of the 
MHC class I molecules has been detected [Wainwright et al., 2000]. Surface expression of HLA-F 
has primarily been detected on EVTs and B-cell lines even though one study presented results 
demonstrating the presence and transcription of HLA-F in a T cell line [Shobu et al., 2006; Lee et 
al., 2003; Wainwright et al., 2000; Lepin et al., 2000]. Upon binding to β2-microglobulin, HLA-F was 
found to interact with ILT2 and ILT4 [Lepin et al., 2000]. However, ILT2 and ILT4 are not specific for 
HLA-F since the HLA-G protein has been found to interact with these ILT molecules. Furthermore, 
HLA-F has been found to be able to interact with ILT2 on the surface of monocytes but not on NK 
cells expressing ILT2. Since ILT2 binds to class I molecules through their α3-domain, the possibility 
of receptors with affinity to bind the α1 and α2 regulating the binding groove of HLA-F exists [Lepin 
et al., 2000]. Another hypothesis is that HLA-F through interaction with ILT2 and ILT4 can 
modulate the activation threshold of immune effector cells [Lepin et al., 2000]. Yet another 
hypothesis about the function of HLA-F is that it does not have a peptide dependent surface 
expression but is dependent on its cytoplasmic tail in order to be expressed on the cell surface 
[Boyle et al., 2006]. Thus, polymorphisms in exon 8 of the gene encoding the cytoplasmic tail are 
of great importance for the surface expression of the HLA-F protein and can cause a 
downregulation of cell presentation of HLA-F. Even though different studies implicate different 
functions of HLA-F, the immunological role of HLA-F is yet to be fully defined.  
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Summary & Perspectives  
Based on the literary knowledge we have obtained through this review, it is clear that the studies 
of HLA-F are very few. Several studies have demonstrated that the HLA-G and HLA-E genes may 
have an impact on the maintenance of pregnancy indicating a possible correlation between RSA 
and the mentioned genes. HLA-G and HLA-E have been shown to inhibit and regulate NK cell 
activity. Furthermore, it has been shown that the HLA-E and HLA-G proteins may have an 
important function in protecting the fetus against the maternal immune system during a normal 
pregnancy.   
Studies have suggested that HLA-F has an influence on the environment of fetal growth during 
pregnancy. HLA-F is expressed on the cell surface of EVT cells and increases from the second 
trimester and through the rest of the pregnancy. Some polymorphisms of HLA-F may have an 
influence on the expression pattern of HLA-F on EVT cells, thus polymorphisms may have an 
impact on fetal rejection during pregnancy. However, these assumptions are very speculative since 
HLA-F is not investigated in more detail. The involvement of the other HLA class Ib proteins in the 
stimulation and inhibition of maternal decidual NK cells and their immunosuppressive function, 
suggests a similar role for HLA-F.   
Both HLA-G, HLA-E, and HLA-F are oligomorphic and distribution of certain genotypes have 
been associated with RSA. However different results have been obtained in different studies of 
various populations indicating that HLA class Ib genes are of minor importance or that other 
factors also play a role in a successful pregnancy. 
Based on the lack of investigation of the HLA-F gene and its low degree of polymorphism, we 
have chosen to perform an experimental study of this gene in relation to RSA .The results from this 
study will be presented in Part II. Several studies imply that genetic polymorphism might be 
correlated with the occurrence of RSA, hence the object of this study will be to further elucidate 
the connection between HLA-F and RSA.  
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Part II:  
Association of the HLA-F genotype on the development of Recurrent Spontaneous 
Abortions – a study of the 5’ URR and 3’UTR of HLA-F  
 
Introduction 
Throughout pregnancy, the maternal immune system is in close contact with cells and tissues from 
the semi-allogeneic fetus. Hence, mechanisms maintaining a balance between the maternal and 
fetal immune systems must exist in order to ensure that the fetus will not be rejected by the 
mother. It can be hypothesized that an imbalance in such mechanisms might result in pregnancy 
complications such as Recurrent Spontaneous Abortions (RSA). Several studies demonstrate the 
association of the HLA genes with the development of RSA. Especially, the non-classical HLA genes, 
HLA-E, -F, and -G, might be linked to RSA and are thought to be implicated in the achievement of a 
successful pregnancy since these genes are the only HLA molecules expressed by trophoblast cells 
in the placenta [Kovats et al., 1990; Ishitani et al., 2003]. Increased evidence suggests that these 
proteins have immune regulatory functions and may influence the development of tolerance 
towards the fetus. HLA-G seems to have an influence on the modulation of the maternal immune 
system and thereby the acceptance of the semi-allogenic fetus [Carosella et al., 1999; Ishitani et 
al., 2003]. HLA-G and HLA-E have shown to inhibit and regulate NK cell activity. Hence, these 
proteins may function as key components in the protection of the fetus from the maternal 
immune response during pregnancy [Tripathi et al., 2006]. The function of HLA-F is yet to be 
elucidated due to the fact that this gene is the least investigated among the HLA genes. HLA-F 
displays low allelic polymorphism, which is why we want to study a possible association between 
these polymorphisms on HLA-F and the development of RSA. Most common polymorphisms often 
occur in introns, 3’ UTR of DNA, and in the nucleotide positions in codons which do not result in an 
amino acid changes thus causing synonymous polymorphisms. This is believed to be due to natural 
selection which ensures the elimination of deleterious polymorphisms. We focus on the 5’ URR 
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and 3’ UTR due to the hypothesis that these DNA sequences may be regulatory. Studies have 
suggested that changes in the regulatory regions affect evolution of shape, physiology, and 
behavior. Both 5’ and 3’ DNA sequences contain signals for transcription. Furthermore, 
polymorphisms in the 3’ UTR sequence may influence the speed and accuracy of transcription as 
well as translation. Thus, polymorphisms of these regions may have possible influences on RSA, 
which is why these regions of the HLA-F gene are investigated in this study [Griffiths et al., 2008].  
In this case-control study, we apply polymerase chain reaction (PCR) to amplify the specific DNA 
sequences in the 5’ URR and 3’ UTR of random DNA samples from women experiencing RSA and a 
fertile control group. Due to a limited time frame, we have not been able to complete the 
commenced experiment. Hence, data obtained in this study is only introductory. Thus, in this pilot 
study, we provide data for further studies regarding the possible implication of polymorphisms in 
HLA-F in the development of RSA. Sequencing of the introductory DNA samples are presented 
along with a theoretically based statistical analysis in which differences between the allelic 
polymorphisms among women with RSA and the control group are studied.   
Materials and Method  
Patients and controls  
The data presented in this study is based on randomly collected introductory DNA samples. The 
results from the following executed experiment are not presented in this project due to a limited 
time frame. However, our cohorts are selected based on following criteria. The experiment were 
conducted based on data from 28 women affected with unexplained RSA and a control group of 
30 healthy women with two or more uncomplicated pregnancies and live births. All women with 
unexplained RSA have undergone a screening program consisting of hysterosalpinography or 
hysteroscopy, midluteal serum progesterone, serum thyroxine, and karyotyping of the couple. 
Furthermore, most of them have been screened for antibodies to cardiolipin and lupus 
anticoagulant. Women from the control group had two or more uncomplicated pregnancies and 
live births [Hviid et al., 2002].   
Polymerase Chain Reaction (PCR)                                                                                                                 
We have conducted three different types of PCR, Genotyping Master (Roche, LightCycler® 480 
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Genotyping Master 04 707 524 001), DreamTaq DNA Polymerase kit (Fermentas), and Probes 
Master (LightCyclerr® 480 Probes Master).  
Two sets of primers were designed for HLA-F (Chromosome 6:29691117-29694302), using USCS 
Genome Database [12], see Appendix I.  
PCR-primer Forward Reverse 
HLA-F 5’ URR region 5’ CGCGGTGGCTCATGCCTGTAATC 3’ 5’ AACCTCCGCGTCTGGGAAA 3’ 
HLA-F 3’ UTR region 5’ TGCACTTGTGCCTCACGAACATACATAAA 3’ 5’ GGTCCTTAGGAGGCATAGCAGTTAGAG 3’ 
 
The amplification with Genotyping master was performed in a 50 µL mixture containing 5 µL 
genomic DNA, 10 µL primers (5 pmol/µl for each primer), and 10 µL PCR mix (5xconcentration). 
The preparation was added up with water to yield a total reaction mix of 50 µL. The amplification 
with Probes master was performed in a 50 µL mixture containing 2.5 µL genomic DNA, 2 µL 
primers (5 pmol/µl for each primer), and 25 µL Master mix. The concentration of the genomic DNA 
is 50-100 ng per 50 µl PCR mix (5xconcentration).  
The PCR program is the same for both kits. The reaction was preincubated at 95 °C for 10 min, 
then subjected to 40 cycles of 94 °C denaturation for 10 sec, 60 °C annealing for 1 min and 72 °C 
elongation for 3 min. After the 40 cycles, the reaction was cooled down to 40 °C. 
   DreamTaq DNA Polymerase kit (Fermentas) was used in another PCR setup. Likewise, 
amplification was performed in a 50 µL mixture containing 5 µL genomic DNA, 10 µL primers (5 
pmol/µl for each primer), 5 µL 10× DreamTaq Buffer and 0.5 µL Taq polymerase. The reaction was 
denatured for 2 min at 95 °C, following 40 cycles of 30 sec denaturation at 95 °C, annealing 60 sec 
at 60 °C and extension 210 sec at 72 °C, followed by a final extension of 10 min at 72 °C. 
Based on gel pictures from the three PCR kits, as shown in the results section, we decided to 
proceede with Genotyping Master.  
DNA Sequencing  
The nucleotide sequence of the LightCycler PCR and PCR products of the 5’ URR and 3’ UTR were 
determined by sequencing. The following primers were used for sequencing:  
Sequencing primer Forward Reverse 
HLA-F 5’ URR region 5’ GTAATCGCAGCACTTTGGGAGGCCG 3’ 5’ CGCGGGACTCATATTTTTCCCAGAC 3’ 
HLA-F 3’ UTR region 5’ GCCTCACGAACATACATAAATTTTAAAAAT 3’ 5’ CCCCTGATGCCTTTAACTTTTTTCCTCT 3’ 
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Results 
Three different sets of PCR reactions were used for optimizing the PCR setup: LightCycler®480 
Master Genotyping, LightCycler®480 Probes Master, and DreamTaq
TM
 DNA Polymerase. 
Furthermore, we used both LightCycler PCR and traditionally PCR. In the beginning of this case-
control study, we began working on both HLA-E and HLA-F, however due to a limited time frame 
we chose only to focus on the HLA-F gene for the further experiment.   
The first PCR reaction is conducted with Master Genotyping and the samples are run on a 
LightCycler PCR instrument, after which gel electrophoresis at 250 volts is performed. For each 
sample pictures in the range of 3-8 min are taken.  
In the second PCR reaction, all three sets were used. LightCycler PCR is optimized used for short 
sequences. Due to the relatively long length of our sequences, which are approximately 1000-1200 
bp. DreamTaq was used, which is run on traditional PCR which is optimized for longer sequences. 
Below, the gel pictures show the PCR products for all three reactions.  
 
.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 shows the gel picture of DreamTaq after 5 min 
at 250 volts. FP = HLA-F 5’ URR, FU = HLA-F UTR, EP = HLA-
E 5’URR, EU = HLA-E UTR and B = blind test.   
Figure 15 shows the gel picture of Probes Master after 
7 min at 250 volts. FP = HLA-F promoter, FU = HLA-F 
UTR, EP = HLA-E promoter, EU = HLA-E UTR and B = 
blind test.    
Figure 13 shows the gel picture of Master 
Genotyping after 7 min at 250 volts. FP = HLA-F 5’ 
URR, FU = HLA-F 3’ UTR, EP = HLA-E 5’ URR, EU = 
HLA-E UTR and B = blind test 
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The gel picture with DreamTaq shows very small fragments. The opposite is the case for the 
samples performed with Probes Master. For these the bands are smeared, which is why the 
specific fragment length not can be measured. On the Master Genotyping gel, clear bands which 
are consistent with the expected length are observed, hence we choose to continue with the 
Master Genotyping mastermix and use the LightCycler PCR.  
In the third PCR reaction, we continued with Master Genotyping. Gel electrophoresis with two 
different charges was used; 250 V and 120 V. Pictures of the gel electrophoresis are shown in 
Figure 17, Figure 16 and Figure 18.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The change of the voltage in Figure 17 had no effect in relation to the quality of the bands in 
the gel. All the samples in Figure 16 containing HLA-F 5’ URR sequences were expected to have a 
length of approximately 1200 bp but on this picture they are approximately 800-900 bp long. In 
Figure 18, all samples containing HLA-F 3’ UTR sequences are found to be approximately 1000-
1200 bp, and these were expected to be around 1100 bp. All the samples of the 5’ URR sequences 
seem to be shorter but the 3’ UTR sequences are about the right size. The shorter sequence 
Figure 17 shows the gel picture of Master 
Genotyping for HLA-F after 20 min at 120 volts for 
both 5’URR and 3’ UTR. 
Figure 16 shows the gel picture of Master 
Genotyping for HLA-F 5’ URR after 7 min at 250 
volts. The well between P4 and P5 is empty.  
Figure 18 shows the gel picture of Master 
Genotyping for HLA-F UTR after 7 min at 250 volts 
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observed for the 5’ URR sequences can be explained by unknown deletions or insertions, which 
requires further studies.  
On the basis of these results, another PCR with HLA-F was performed and the obtained PCR 
products products were submitted to sequencing.    
Sequencing  
The following section will provide an overview of the obtained sequences of the 5’ URR and 3’ UTR 
of the HLA-F gene and the consensus sequence. The sequencing results of the HLA-F PCR products 
are compared to the HLA-F gene sequence, and are available in Appendix II. 
For the 5’ URR, only parts of the forward strands match the consensus sequence, and these 
samples are marked with yellow. For the 3’ UTR, both parts of the forward and reverse strands 
match, and the forward are marked yellow, whereas the reverse strands are marked green.  
The sequencing results of both the 5’ URR and the 3’UTR did not yield the correct lengths, 
moreover the 5’ URR sequence showed a poorer match compared to 3’ UTR. None of the 
reverse/complementary strands in the 5’ URR matched with the consensus sequence. This 
indicates that the reverse primer did not function correctly.  
Generally, the 5’ URR sequences are not very useful to determine any polymorphism due to few 
matches with the consensus sequence of HLA-F, which is why these results are not applicable.  
As for the 3’ UTR, larger parts of the sequenced samples match the consensus sequence, thus 
indicating amplification of the correct sequence, but due to sequencing problems, this can not be 
demonstrated on the basis of current sequences. Furthermore, a TGTGTG deletion was found in 
nearly all the sequenced samples. This finding may be explained with technical errors, which 
appeared in the sequencing procedure.  
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Statistical analysis 
The purpose of the statistical analysis is to examine if the outcome of the experimental study 
provides statistical significant results. For this purpose, a Chi
2
 (χ2) test is performed in order to 
examine whether the observed data follows the expected distribution. Furthermore Fisher's exact 
test which is more accurate and gives a better estimate of the distribution of the observed data if 
the observed numbers are small is performed. The allele frequencies of the two groups under 
study are tested for the Hardy-Weinberg equilibrium, using Chi
2
-tests. 
Chi-square (χ
2
) 
The Chi-square (χ
2
) test can be used for two purposes; determining whether or not there is a 
difference in the HLA-F polymorphism distribution in the cohort with RSA women and fertile 
women. Furthermore, it can also been used to examine whether a significant difference between 
the two groups under study, is evident.  
In this part, we will study whether there is a significant difference between the two groups 
under study.  Before the expected values can be determined, we need to define a null hypothesis. 
The null hypothesis states that there is no difference between the HLA-F genotype distribution 
between women with RSA and fertile women.  
The following section contains an overview of the application of the χ
2
-test based on fictive 
data due to the fact that we have not obtained any applicable data during this case-control study.  
Observed values 
Allele F*0104 SNPs RSA Control Total 
SNP C 142 112 254 
SNP A  113 133 246 
Total 255 245 500 
The fictive allele proportions are: 
255/500 for RSA, 245/500 for control, 254/500 for SNP C and 246/500 for SNP A 
The expected values can be calculated by multiplying the allelic proportions, e.g. in order to 
determine expected amount of the RSA/SNP C; 
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Expected value for RSA/SNP C = (255/500) x (254/500) x 500 = 129.54  
Expected values  
Allele F*0104 SNPs RSA Control Total 
SNP C 129.54 124.46 254 
SNP A  125.46 120.56 246 
Total 255 245 500 
The χ
2 
value can now be calculated by using the following formula: 
 
 
 Observed Expected (O-E)
2
/E 
RSA/ SNP C 142 129.54 1.19 
Control/ SNP C 133 120.56 1.29 
RSA/SNP A 113 125.46 1.24 
Control/ SNP A 112 124.46 1.25 
Total (χ
2
) = 4.97 
The degrees of freedom equal the number of observations in a data set subtracted with the 
number of parameters estimated in the study. The determined χ
2 
value can be used to calculate 
the probability, p, by using the χ
2 
table.  When looking at the χ
2 
table, we see that our χ
2 
value is 
close to 5.021 with a probability of 2.5 percent. Since this probability is < 0.05, the null hypothesis 
can be rejected meaning that there is a difference between the HLA-F genotype distributions 
between the two groups. If the p-value is > 0.05, the null hypothesis is accepted indicating no 
significant differences between the HLA-F genotype distributions between the two groups under 
study [Griffiths et al., 2008].  
 





 −
∑=
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Fisher’s exact test  
Fisher’s exact test expresses the distribution of the two alleles under study.  
Allele F*0104 RSA Control  Total 
SNP C  142 112 254 
SNP A 113 133 246 
Total 255 245 500 
 
The lowest value observed is designated q. In this example q equals 112.  
Furthermore, we have to revalue the possible q+1 tables with a value less than or equal to q.  
It is also possible to use software programs to calculate these probabilities [8]. The determined p-
value of our fictive data is calculated as 0.032 ≈ 3.2 %. This value indicates that the association 
between the two groups, RSA and control, is considered to be statistically significant. The p-value 
in this test is almost the same as the χ
2
 test [Skovgaard et al., 1999].  
Hardy-Weinberg equilibrium and the Chi
2
 test  
The χ
2
-test can as previously mentioned be used to examine whether the allele frequencies of the 
two groups under study are in accordance with the Hardy-Weinberg equilibrium. This enables us 
to state if random mating results in equilibrium of genotype frequencies in a population.  
  The Hardy-Weinberg law determines the probability of the inheritance of one allele in the next 
generation. This law further states that the frequency of alleles and genotypes are constant in a 
population as long as this consists of many organisms; random mating is evident; all organisms 
have the same probability to survive and are fertile; no mutations or any immigration and  males 
and females do not differ in terms of their allele frequencies.   
P and q indicate the allele frequencies, and the following law applies: p + q = 1  
Hardy-Weinberg equilibrium determines the relationship of the allele frequencies by this rule: p
2
: 
2pq: q
2
 which can be used to calculate the expected allele frequencies.   
 
 
[48] 
 
- A/A, homozygote p
2
 
- A/C, heterozygote 2pq 
- C/C, homozygote q
2
 
The sum of the three genotypes frequencies is equal to one;   
P
2
 + 2pq + q
2
 = 1 
The χ
2
-test can also been used for the equality of distributions, which will be shown in this section 
as an integrated part of the Hardy-Weinberg test. In this example we look at the distribution 
between the genotypes in the RSA group.   
Genotype F*0104 SNPs RSA 
 C/C C/A A/A Total 
Observed  36 47 23 106 = N 
Frequencies expected P
2
 2pq q
2
 = 1,00 
Numbers expected P
2
N 2pqN q
2
N = N 
Numbers expected  33.2 52.3 20.5 = 106 
Aberration 2.8 -5.3 2.5  
Chi
2
 (χ
2
) 0.24 0.54 0.31 1.09 
 
The expected frequencies are calculated by finding p and q values: 
 
 
 
Then, by calculating the expected numbers of each genotype: 
 
 
The aberration is determined by:  
Aberration = Observed – Expected numbers = 36 – 33.2 = 2.8 
And now we can calculate the χ
2
 for the three genotypes, where we used the same formula as in 
the first section of χ
2
: 
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The degrees of freedom equal the number of observations in a data set subtracted with the 
number of parameters estimated in the study. The test has one degree of freedom, since there are 
three classes, and because there are only used two free parameters p and N to calculate the 
expected number. The last parameter q is not a free parameter because it can be calculated as 1 –
p. By looking at the χ
2
 table, we can see that the calculated χ
2 
value can be used to calculate the p 
value by using the χ
2 
table. In this example, we have obtained a p value > 0.05, thus we can 
conclude that the distribution of the alleles is random. Thus, the null hypothesis applies. However, 
if a p value < 0.05 was obtained, the null hypothesis could be rejected [9].    
Type I and Type II errors  
A test of a hypothesis can go wrong in two ways.  
A type I error occurs when a true hypothesis is being rejected and the Type II errors occurs when 
an untruthful hypothesis is accepted [13]. Bonferroni correction can be used to detect a statistical 
significance in cases where a number of alleles are detected. The correction gives an estimate of 
the probability of the significance of at least one of the detected alleles [10].  
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Discussion 
 
The sequencing of the 5’ URR showed no significant matches to the reference HLA-F sequence, 
which might be caused by the application of too much DNA. As the amount of DNA yield from the 
PCR reaction is dependent on the number of PCR-cycles in the PRC-program, a lowering of the 
cycles to 30 or 35 PCR-cycles may provide a better sequencing. Additionally, the TGTG repeat 
sequence found in the end of the HLA-F reference sequence may cause sequencing problems, for 
which reason a redesign of the primers at a different location might also improve the sequencing 
results. Thus, optimization of the circumstances behind the DNA-sequencing is required. The HLA-
F3UTR4_GATC-SEKHLAF_RU4_352200 (9) sample suggests that sequencing of HLA-F 3’ UTR was 
obtained, but in order to analyze the samples, more optimizing is required, which is not possible 
due to the limited time frame. The TGTGTG deletion in the beginning of the HLA-F 3’ UTR, which is 
seen in all of the obtained sequences, is possibly a result of DNA-polymerase reading problems, 
because of the repeats. The limited time frame available for the project did not allow us to go 
through with the technical optimizing procedures of the DNA-sequences of 5’ URR and 3’ UTR 
needed to obtain results for the intended case-control study. Despite the lack of data, examples of 
the data analysis optimal for such datasets are shown. 
To further investigate the role of the HLA-F polymorphisms in the development of RSA, several 
factors are to be denoted in the conduction of such a study. A question that arises is the choice of 
DNA samples for the study. The primary approach would be a case-control study comparing the 
DNA sequences of women with RSA with those of fertile women. Based on the data from the 
sequencing results of these DNA samples, the distribution of polymorphisms in women with RSA 
and fertile women could be examined. A factor that may play an important role in the outcome of 
such results is the choice of women for the two groups. As the definition of RSA is not fully 
definitive, the criteria for selection of cohorts for studies with RSAs are different for different 
studies. It can be argued that a random selection of women for each group does not represent the 
wanted groups because such two groups would not have been cleared for other diagnoses as the 
samples have been taken from a random time in their lives, therefore not providing the full 
spectre of their fertility. For the group of fertile women, the sampling is done without any possible 
chance for taking into account that the women may have experienced unwanted abortions very 
early in the pregnancy, or the possibility that they may develop RSA at another point of their lives. 
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For the group of women with RSA, the possibility of a successful pregnancy in the future remains.  
To overcome these uncertainties, a study could be made in which DNA was only obtained from 
menopausal women whose medical records showed no complications that might be implicated in 
the development of RSA. Also, the fertile control group would be more precise as their medical 
records would prove no known abortions during their reproductive age. Strict criteria in the 
selection of women for the study might lead to a more righteous distribution of genotypes and 
therefore provide more clarity to the question of the implication of HLA-F polymorphisms in RSA. 
Another approach in obtaining more precise results concerning the genetic importance of HLA 
polymorphisms on pregnancy complications is through conduction of case-control studies using 
family triads, as paternal factors have been suggested to contribute to pregnancy complications 
[Need et al., 1983; Dekker et al., 1998; Hoy et al., 1999; Eras et al., 2000; Robillard et al., 1993; 
Koelman et al., 2000]. 
The impact of HLA-F polymorphisms on pregnancy 
The occurrence of polymorphisms and mutations in HLA-F can be hypothesized to be critical to the 
expression of the protein on the surface of trophoblast cells. Conserved sequence repeats such as 
AU-rich elements, AUUUA, in the end of the HLA-F gene may influence its mRNA stability as well as 
the level of surface expression. Polymorphisms in genes containing this sequence may result in the 
transcription of an unstable mRNA and thus a low level of translated protein, which can both 
influence the surface expression and the peptide binding of HLA-F.  As HLA-F is thought to play an 
important role in the maintenance of tolerance during pregnancy along with the other HLA class Ib 
proteins and HLA-C, a decrease or no surface expression at all can lead to a shift in balance, thus 
allowing cytotoxic immune responses towards the fetus. Even though the peptide binding of HLA-F 
has not been elucidated, polymorphisms and mutations in the gene can furthermore be thought 
to be implicated in changes in the peptide binding groove of HLA-F. The lacking ability of HLA-F to 
bind peptides will thus result in a restricted surface expression, as the binding of peptide is 
essential for HLA-F to be expressed on the surface.  
An imbalance in one of these mentioned factors may result in reduced tolerance against the 
fetus, as HLA-F is found to be expressed on trophoblast cells in the feto-maternal interfase. The 
expression of HLA-F is found to be highest during the second trimester of pregnancy [Shobu et al., 
2006] indicating that this gene plays a role in fetal growth. HLA-E, on the other hand, has shown 
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surface expression already from the first trimester of pregnancy. HLA-G is found to be expressed 
on the surface of cells and in the cytoplasm throughout the pregnancy. Shobu et al. [2006] 
conclude that the increased concentrations of HLA-F and -E are correlated with increased fetal 
growth, suggesting the important role of these proteins in establishing an optimal environment for 
the fetus to allow its proper growth. The simultaneous expression of HLA-G, -E, and -F can be 
postulated to be a mechanism allowing the maintenance of tolerance during pregnancy as the 
expression of the genes can be thought to co-exist in order to maintain tolerance in the absence of 
one of the genes.  
Though more extensive studies are required in order to detect differences and similarities in 
the expression of these genes, polymorphisms resulting in diminished expression of HLA-F might 
prove to be harmful to fetal growth and might thus be implicated in fetal rejection. As 
polymorphisms in HLA-G have been proven to occur at a significantly higher rate in women with 
pregnancy complications such as pre-eclampsia, the role of HLA-F may also prove to be 
comparable to that of HLA-G. 
Pregnancy complications characterized by polymorphisms in the 3’ UTR of HLA-G 
The untranslated regions of HLA-G which are immunologically active and are expressed on 
trophoblast cells along with HLA-E and -F (and HLA-C) have been found to have regulatory effects 
on the gene products. Several studies have reported the linkage to pregnancy complications with 
polymorphisms in the untranslated regions of HLA-G suggesting that these regions of the gene are 
implicated in dysfunctions in the proteins encoded by them. 
The implication of the HLA-G 14 bp insertion/deletion polymorphism in pregnancy has been 
investigated suggesting an affect of the polymorphism on the HLA-G mRNA stability [Hviid et al., 
2003; Rousseau et al., 2003]. Both pre-eclampsia and RSA have been investigated though different 
results have been obtained concerning the implication of the polymorphism in the development of 
the respective pregnancy complication. 
The HLA-G 14 bp insertion polymorphism has been found in significantly higher amounts in 
pre-eclamptic women as for fertile women [Larsen et al., 2010]. Larsen et al. [2010] have 
conducted a haplotype-specific PCR experiment amplifying and sequencing the 3’ UTR of the HLA-
G gene. The 14 bp insertion/deletion polymorphism was investigated in this study. 50 pre-
eclamptic patients and 85 control subjects were studied and a significant association with pre-
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eclampsia was found for fetuses containing the haplotype homozygous for the +14 bp insertion 
polymorphism in the HLA-G gene, which is consistent with results from other studies. The fetal 
homozygous genotype, +14/+14, has been found to constitute a significantly increased risk of pre-
eclampsia in primiparas [O’Brien et al., 2001; Hylenius et al., 2004]. A case-control study of 155 
family triads of mother, father, and newborn by Hylenius et al. [2004] suggests that the observed 
differences in genotypes between pre-eclamptic women and fertile control women are a result of 
different contributions of the 14 bp insertion/deletion polymorphism from the father. The study 
further suggests a significant overrepresentation of the +14/+14 bp HLA-G genotype in offspring. 
Furthermore, combined mother-child genotypes are found as a risk factor in the development of 
pre-eclampsia.   
The association of the 14 bp polymorphism in women with RSA is somewhat uncertain since 
the few studies concerning the influence of HLA-G alleles on the development of RSA show no 
consistency. A pilot study in which the +14/+14 genotype was found in four out of 14 non-
pregnant women in comparison to no observed homozygotes in the fertile group consisting of 15 
women with a successful twin-pregnancy, was found to be similar to the data obtained in a study 
of 61 RSA women and 93 fertile women with at least two successful pregnancies in which an 
association of the homozygous +14 bp polymorphism genotype was found in women with RSA 
[Hviid et al., 2002; Hviid et al., 2004(a)]. Contrary to these results, Abbas et al. [2004] and Tripathi 
et al. [2004] found a higher incidence of a heterozygous genotype for the 14 bp polymorphism in 
Indian women with RSA. These different results may be due to differences in selection criteria in 
the different studies. Though different alleles within HLA-G have been suggested to be implicated 
in the development of RSA, studies point at the association between the 14 bp insertion 
polymorphism in the 3’UTR with RSA, as the levels of sHLA-G have been shown to be decreased in 
women with RSA compared to fertile women [Aldrich et al., 2001; Hviid et al., 2002; Pfeiffer et al., 
2001; Hviid, 2006(a); Pfeiffer et al., 2000]. However, these findings could not be reproduced in a 
study conducted by Iversen et al. [2008] who showed that neither the maternal nor the fetal 14 bp 
genotype is associated with fetal growth or with an increased risk of pre-eclampsia.   
As polymorphisms in the 3’ UTR of HLA-G have been proposed to influence the mRNA stability, 
it can be hypothesized that the other HLA class Ib genes, HLA-E and HLA-F, might have as 
important SNPs influencing the immunity against the semi-allogeneic fetus and the development 
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of RSA as well as other pregnancy complications, as the trophoblast cells which originate from the 
fetus express only class Ib antigens along with a weak expression of HLA-C [King et al., 2000]. The 
immunological role of HLA-E has been found to have some roles similar to those of HLA-G in the 
development of tolerance against the fetus, thus HLA-F is most likely to account for similar 
functions during pregnancy. Additionally, HLA-G is proved to bind to the inhibitory receptor ILT2 of 
maternal decidual NK cell leading to a possible immunosuppression of NK cells [Bashirova et al., 
2006; Allan et al., 1999; Biassoni et al., 1999; Colonna et al., 1998; Shiroishi et al., 2003]. Hence, a 
similar function for HLA-F is postulated. The hypothesis of the interaction between HLA-F and ILT2 
and ILT4, which are receptors thought to control inflammatory responses and cytotoxicity found to 
be expressed on maternal decidual NK cells, suggests an immunomodulatory role of HLA-F in the 
development of tolerance [Lepin et al., 2000; Allan et al., 2002]. The immunological balance at the 
feto-maternal interphase may be affected as a result of NK cell inhibition.  
The role of HLA molecules in autoimmune diseases 
 
The non-classical MHC molecule HLA-G has been found to promote important roles during organ 
transplantation [Hviid, 2006(b)]. Especially high levels of sHLA-G expression is found to be 
associated with significantly improved prognosis following transplantation, thus indicating the 
immunomodulatory role of sHLA-G in the development of tolerance [Lila et al., 2002; Creput et al., 
2003]. Since polymorphisms in HLA-G have been found to be implicated in several autoimmune 
diseases, these polymorphisms might serve as molecular markers in the diagnosis of people which 
are at risk for developing specific autoimmune diseases and pregnancy complications. 
Studies indicate an association between the HLA class II genes and RSA and pre-eclampsia 
[Hviid & Christiansen, 2005]. Christiansen et al. [1999] observed that polymorphisms and alleles of 
the HLA-DRB1 locus are involved in the development of RSA. Hviid & Christiansen [2005] have 
found that a specific HLA-G allele is in linkage disequilibrium with a haplotype consisting of the 
HLA-A1, -B8, -DR3, and -DQ2 alleles. This haplotype and HLA-G is involved in autoimmune diseases 
such as type I diabetes [Svejgaard et al., 1983; Kumar et al., 2009].   
A balanced immune response is ensured by Treg cells maintaining two functions; recognizing 
self-antigens as harmless and fighting pathogens at the same time [Kelsen et al., 2006]. The 
majority of endogenous Treg cells express CD4, CD25, and Foxp3 simultaneously and this cell 
population has been found to suppress pathological and physiological immune responses, thus 
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playing a key role in preventing autoimmune diseases and in the establishment of the 
development of tolerance [Sakaguchi, 2005]. Amodio et al. [2010] have found that membrane-
bound HLA-G1 constitutes a major role in the induction of Treg1 supporting the suggested role of 
HLA-G as a major component in the development of tolerance. Defects in Treg cell function might 
contribute to the development of autoimmune diseases such as rheumatoid arthritis (RA) and type 
I diabetes mellitus [Kelsen et al., 2006]. 
During pregnancy, some autoimmune diseases worsen in contrast to others being improved. 
An autoimmune disease which improves during pregnancy is RA [Nelson et al., 1993]. The fact that 
HLA-G is implicated in autoimmune diseases further supports the immunomodulatory function of 
HLA-G. RA is believed to be correlated with a dominance of the Th1 response [Ostensen & Villiger, 
2002]. The fact that this condition improves during pregnancy supports the finding that a healthy 
pregnancy is correlated with a dominant Th2 response. RA patients are, however, in a risk zone of 
developing RSA [Wolfberg et al., 2004].     
Experiments indicate that the HLA-G protein is implicated in the shift of the Th1 to the Th2 
response during pregnancy. The condition intrahepatic cholestasis of pregnancy can cause 
premature parturition and sudden intrauterine fetal death [Yayi et al., 2010]. Patients having this 
condition are found to express HLA-G in lower levels, than fertile women, in the placenta. A 
dominance of the Th1 response is also observed in the placenta of these patients. Hence, HLA-G is 
indicated to be important for the immunological shift of the Th1/Th2 responses [Yi & Ding, 2010].  
As previously mentioned, HLA-G inhibits NK cells as well as Tc cells, and HLA-E inhibits the 
cytotoxic function of NK cells. Since both HLA-G and HLA-E interact with decidual NK cell receptors 
and as the structure of HLA class I molecules is similar, the likewise similar function of HLA-F is 
hypothesized. Thus, the HLA-F protein might play an important role in autoimmune diseases as 
well as pregnancy conditions such as RSA and pre-eclampsia. Furthermore, if this theoretical 
hypothesis applies, polymorphisms in the HLA-F gene may be implicated in both autoimmune 
diseases and pregnancy complications due to the immunological function of the HLA class I 
molecules. 
To determine the molecular and immunological functions of HLA-F, both genetic studies and 
molecular studies examining the expression of HLA-F and the binding of peptides, are required. 
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Genetic studies as the present are required in order to determine differences in the 
distribution of polymorphic alleles in RSA patients and fertile women. As several studies have 
already indicated an association between HLA-G and pregnancy complications, such as pre-
eclampsia, similar studies with larger cohorts and more stringent criteria in the selection of test 
subjects conducted on HLA-E and -F, are likely to present results corresponding to the ones found 
for HLA-G. 
Molecular studies in which transformations in cells that do not normally present HLA-F 
proteins on the cell surface; are done, would provide a clearer picture of the factors necessary for 
the surface expression of HLA-F. Antibody-mediated binding of HLA-F could furthermore be 
conducted, providing an insight into the peptides bound by HLA-F. Additionally, this would provide 
a better view of the factors in which HLA-F is implicated e.g. influencing the secretion of cytokines 
at the feto-maternal interfase involved in the development of tolerance during pregnancy. 
Although knowledge about the functional significance of the non-classical HLA Ib molecules is 
growing, more basic research is still required in order to gain more insight into the regulatory 
network in the development of tolerance, which is hypothesized for the non-classical HLA Ib 
molecules.  Further studies within the molecular mechanisms and pathways, which are involved in 
the function of HLA-F, and which might be disrupted as a result of polymorphisms in this gene are 
desired.  
The hypothesis of the implication of the non-classical HLA Ib molecules in pregnancy and organ 
transplantation as a result of their immunomodulatory functions is yet to be identified. Thus, the 
question whether the non-classical HLA-molecules prove to play key roles in the regulation of the 
immune system requires further studies [Hviid 2006(a)]. 
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p
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